

09/757,011

=> d his

*search of applicants
species*

(FILE 'HOME' ENTERED AT 09:46:52 ON 12 SEP 2003)

FILE 'CAPLUS' ENTERED AT 09:46:59 ON 12 SEP 2003

L1 33 S OGNANOV V?/AU
L2 48 S BORDEN L?/AU
L3 1071 S BELL S?/AU
L4 24877 S ZHANG J?/AU
L5 4 S L1 AND L2 AND L3 AND L4
L6 4 S L5 AND PATENT/DT
L7 1 S US6191165/PN
L8 1 S L6 AND L7
SELECT RN L8 1-

FILE 'REGISTRY' ENTERED AT 09:48:05 ON 12 SEP 2003

L9 200 S E1-200
L10 168 S E201-368
L11 368 S L9 OR L10
L12 60 S L11 AND NRS=1
L13 286 S L11 AND NRS>1
L14 346 S L12 OR L13
L15 22 S L11 NOT L14

FILE 'CAPLUS' ENTERED AT 09:50:02 ON 12 SEP 2003

FILE 'REGISTRY' ENTERED AT 09:50:14 ON 12 SEP 2003

L16 10 S L12 AND GLYCINE
L17 2 S L16 AND DIBENZO
L18 1 S L16 AND FLUOREN
L19 1 S L16 AND ETHANO?
L20 290 S L13 OR L17 OR L18 OR L19

FILE 'CAPLUS' ENTERED AT 09:56:06 ON 12 SEP 2003

L21 9601 S L20
L22 ANALYZE L21 1- RN HIT : 290 TERMS

FILE 'REGISTRY' ENTERED AT 10:03:46 ON 12 SEP 2003

L23 4 S 54910-89-3/RN OR 92-69-3/RN OR 451-40-1/RN OR 1083-30-3/RN
L24 6 S 19812-93-2/RN OR 2128-93-0/RN OR 712-50-5/RN OR 5586-73-2/RN
L25 280 S L20 NOT (L23 OR L24)

FILE 'CAPLUS' ENTERED AT 10:06:24 ON 12 SEP 2003

L26 1311 S L25
L27 ANALYZE L26 1- RN HIT : 280 TERMS

FILE 'REGISTRY' ENTERED AT 10:10:20 ON 12 SEP 2003

L28 7 S 53179-07-0/RN OR 29558-77-8/RN OR 644-13-3/RN OR 39634-42-9/R
L29 3 S 27064-94-4/RN OR 22679-54-5/RN OR 39186-58-8/RN
L30 270 S L25 NOT (L28 OR L29)

FILE 'CAPLUS' ENTERED AT 10:11:33 ON 12 SEP 2003

L31 282 S L30
L32 ANALYZE L31 1- RN HIT : 270 TERMS

FILE 'REGISTRY' ENTERED AT 10:13:33 ON 12 SEP 2003

L33 5 S 6305-20-0/RN OR 2168-06-1/RN OR 23808-47-1/RN OR 3311-94-2/RN
L34 5 S 14984-21-5/RN OR 32501-12-5/RN OR 6078-95-1/RN OR 49757-42-8/R

09/757,011

L35 260 S L30 NOT (L33 OR L34)

FILE 'CAPLUS' ENTERED AT 10:14:24 ON 12 SEP 2003

L36	17 S L35
L37	12 S L36 AND PATENT/DT
L38	5 S L36 NOT L37
L39	0 S L38 AND 2003/SO
L40	2 S L38 AND 2002/SO
L41	0 S L38 AND 2000/SO
L42	0 S L38 AND 1999/SO
L43	0 S L38 AND 1998/SO
L44	15 S L36 NOT L40


=> d ibib abs hitstr 1-15

09/757,011

L44 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 APPLICATION NUMBER: 2003:610460 CAPLUS
 DOCUMENT NUMBER: 139:165080
 TITLE: Catalyst activators containing Group 13 elements and heteroatom group for ethylene/.alpha.-olefin copolymerization
 INVENTOR(S): Holtcamp, Matthew W.
 PATENT ASSIGNER(S): Univation Technologies, LLC, USA
 SOURCE: PCT Int. Appl., 48 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200306433	A1	20030807	WO 2002-US40743	20021218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2002-5857 A 20020128
 GI



AB A olefin polymn. catalyst system comprises a metallocene catalyst and a catalyst activator having a formula $\text{Cat}^+[\text{M}(\text{JY})\text{x}]^-$, where M = a Group 13 element, e.g. B or Al, (JY) = a heterocyclic group, J = a Group 15 or 16 heteroatom contained in Y, x = the valence of M + 1, Cat^+ = a cation component. The heteroatom group (JY) is represented by the formula I, where X2-X7 is independently selected from H, halogen, an alkyl group, a halogenated or partially halogenated alkyl group, an aryl group, a halogenated or partially halogenated aryl group, an aryl substituted alkyl or a halogenated or partially halogenated aryl substituted alkyl group.
IT 200004-38-2
 RI: RCT (Reactant); RACT (Reactant or reagent)

L44 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 (prepn. of catalyst activators for ethylene/.alpha.-olefin copolymn.)
 RN 200004-38-2 CAPLUS
 CN Benzene, 1,1',1''-(bromomethyldiene)tris(4-fluoro- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 APPLICATION NUMBER: 2003:5918 CAPLUS
 DOCUMENT NUMBER: 138:56244
 TITLE: Preparation of sarcosine aromatic ether derivatives as inhibitors of glycine transport
 INVENTOR(S): Lowe, John Adams, III
 PATENT ASSIGNER(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 47 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000646	A1	20030103	WO 2002-IB1513	20020412
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 2003013887 A1 20030116 US 2002-86037 20020228
 US 6566550 B2 20030520
 PRIORITY APPLN. INFO.: US 2001-299827P P 20010621
 OTHER SOURCE(S): MARPAT 138:56244
 GI



AB Substituted arom. ethers I [A is a ring (Ph, naphthyl, benzothienyl, benzofuranyl, pyridyl, mono- or bicyclic (hetero)aryl not contg. adjacent ring oxygen atoms); X, Y are alkyl, fluoroalkyl, alkoxy, fluoroalkoxy, carboxy, carbalkoxy, carbamido, alkylthio, sulfoxyl, sulfonyl, halo, nitro, cyano, amino, alkylamino, or dialkylamino; B is alkyl, fluoroalkyl, alkoxy, fluoroalkoxy, or halo] or their pharmaceutically-acceptable salts were prepd. as glycine transport inhibitors for use in the enhancement of cognition and the treatment of the pos. and neg. symptoms of schizophrenia and other psychoses in mammals, including humans. Thus, [methyl(3-phenyl-3-[4-[3-(trifluoromethyl)phenoxy]phenoxy]propyl)amino]acetic acid was prepd. by alkylation of sarcosine Et ester hydrochloride with

L44 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 3-phenyl-3-[4-[3-(trifluoromethyl)phenoxy]phenoxy]-1-chloropropane (prepn. given), followed by ester cleavage. Comps. I show significant activity in inhibiting glycine re-uptake in synaptosomes (IC50 values more potent than 10 .mu.M).
IT 200005-62-5P
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREF (Preparation); USES (Uses)
 (prepn. of sarcosine arom. ether deriva. as inhibitors of glycine transport)
 RN 200005-62-5 CAPLUS
 CN Glycine, N-methyl-N-[3-phenyl-3-[4-[3-(trifluoromethyl)phenoxy]phenoxy]propyl]-, hydrochloride (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

(d) no het

09/757,011

applicants

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

ACCESSION NUMBER: 2001:132748 CAPLUS

DOCUMENT NUMBER: 134:178816

TITLE: Preparation of amino acid derivatives as pharmaceuticals for treatment of neurological and neuropsychiatric disorders

INVENTOR(S): Ognyanov, Vassil Iliya; Borden, Laurence A.; Bell, Stanley Charles; Zhang, Jing

PATENT ASSIGNEE(S): Allelix Neuroscience Inc., USA

SOURCE: U.S., 52 pp., Cont.-in-part of U. S. Ser. No.656,063, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6191165	B1	20010220	US 1997-866007	19970530
US 2001012857	A1	20010809	US 2001-757011	20010109
PRIORITY APPLN. INFO.:			US 1996-41503P	P 19960531
			US 1996-41504P	P 19960531
			US 1996-655912	B2 19960531
			US 1996-656063	B2 19960531
			US 1997-44387P	P 19970227
			US 1997-70900P	P 19970227
			US 1997-808754	B2 19970227
			US 1997-808755	A2 19970227
			US 1997-807682	A2 19970228
			US 1997-866007	A3 19970530

OTHER SOURCE(S): MARPAT 134:178816

AB Amino acid derivs. R2RxRyXRINR3 (R3*)nCR4R4*R5 [X = N, C (R2 not present when X = N); R2 = H, alkyl, alkoxy, cyano, alkanoyl, etc.; Rx, Ry = aryl, heteroaryl, adamantyl, or nonarom. ring linked to X via a single bond, alkylene, etc.; R1 = alkylene, iminoxyethylene, etc.; R3 = H, alkyl, (un)substituted Ph or phenylalkyl, etc.; R3* = alkyl, O, n = 0, 1; R4, R4* = H, alkyl, hydroxyalkyl; R5 = (un)substituted carbamoyl, carboxy, aminosulfonyl, phosphoryl, etc.] were prepd. as pharmaceuticals for treatment of neurol. and neuropsychiatric disorders. Thus, N-(4,4-diphenyl-3-butenyl)glycine Et ester was by alkylation of glycine Et ester hydrochloride with 4-bromo-1,1-diphenyl-1-butene. Binding assays to measure interaction of compds. with the glycine site on the NMDA receptor are illustrated.


IT 200004-42-8P 200004-44-0P 200004-51-9P
 200004-52-0P 200004-53-1P 200004-54-2P
 200004-55-3P 200004-56-4P 200004-58-6P
 200004-59-7P 200004-61-1P 200004-62-2P
 200004-66-6P 200004-67-7P 200004-70-2P
 200004-71-3P 200004-73-5P 200004-74-6P
 200004-75-7P 200004-76-8P 200004-77-9P
 200004-78-0P 200004-79-1P 200004-80-4P
 200004-81-5P 200004-84-8P 200004-87-1P
 200004-88-2P 200004-90-6P 200004-96-2P
 200005-05-6P 200005-07-8P 200005-08-9P
 200005-11-4P 200005-17-0P 200005-24-9P

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-53-1 CAPLUS

CN Glycine, N-methyl-N-[3,3,3-tris(4-methoxyphenyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-54-2 CAPLUS

CN Glycine, N-[3,3-bis(3-fluorophenyl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 200004-55-3 CAPLUS

CN Glycine, N-(3,3,5-diphenylpentyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 200004-56-4 CAPLUS

CN Glycine, N-[3,3-bis(4-phenoxypentyl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)


200005-32-9P 200005-34-1P 200005-41-0P
 200005-42-1P 200005-46-5P 200005-49-8P
 200005-51-2P 200005-52-3P 200005-54-5P
 200006-00-4P 200006-07-1P 200006-08-2P
 200006-09-3P 200006-10-6P 200006-24-2P
 200006-25-3P 200006-50-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREF (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of amino acid derivs. as pharmaceuticals for treatment of neurol. and neuropsychiatric disorders)


RN 200004-42-8 CAPLUS

CN Glycine, N-(4,4-diphenyl-3-butenyl)-N-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 200004-44-0 CAPLUS

CN Glycine, N-[2-(9H-fluoren-9-yl)ethyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 200004-51-9 CAPLUS


CN Glycine, N-methyl-N-[3,3,3-tris(4-fluorophenyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 200004-52-0 CAPLUS


CN Glycine, N-(3-cyclohexyl-3-phenylpropyl)-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-58-6 CAPLUS

CN Glycine, N-[3-[4-(1,1-dimethylethyl)phenyl]-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-59-7 CAPLUS

CN Glycine, N-methyl-N-[3,3,3-tris(4-chlorophenyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 200004-61-1 CAPLUS


CN Glycine, N-methyl-N-[3-(2-naphthalenyl)-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-62-2 CAPLUS

CN Glycine, N-[3-(2-naphthalenyl)-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-66-6 CAPLUS
CN Glycine, N-[3-([1,1'-biphenyl]-4-yl)-3-phenylpropyl]-, ethyl ester (9CI)
(CA INDEX NAME)



RN 200004-67-7 CAPLUS
CN Glycine, N-[3-([1,1'-biphenyl]-4-yl)-3-phenylpropyl]-N-methyl-, ethyl ester (9CI)
(CA INDEX NAME)




RN 200004-70-2 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenyl]propyl]-, ethyl ester (9CI)
(CA INDEX NAME)




RN 200004-71-3 CAPLUS
CN Glycine, N-[3-phenyl-3-[4-(trifluoromethyl)phenyl]propyl]-, ethyl ester (9CI)
(CA INDEX NAME)

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-77-9 CAPLUS
CN Glycine, N-[(3R)-3-([1,1'-biphenyl]-4-yloxy)-3-phenylpropyl]-N-methyl-, ethyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 200004-78-0 CAPLUS
CN Glycine, N-[(3S)-3-([1,1'-biphenyl]-4-yloxy)-3-phenylpropyl]-N-methyl-, ethyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 200004-79-1 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]phenoxy]propyl]-, ethyl ester (9CI)
(CA INDEX NAME)




RN 200004-80-4 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]phenoxy]propyl]-, ethyl ester (9CI)
(CA INDEX NAME)


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-73-5 CAPLUS
CN Glycine, N-[3-([4-(1,1-dimethylethyl)phenoxy]-3-(4-fluorophenyl)propyl]-N-methyl-, ethyl ester (9CI)
(CA INDEX NAME)



RN 200004-74-6 CAPLUS
CN Glycine, N-methyl-N-[3-[(6-methyl-3-pyridinyl)oxy]-3-phenylpropyl]-, ethyl ester (9CI)
(CA INDEX NAME)




RN 200004-75-7 CAPLUS
CN Glycine, N-[3-([1,1'-biphenyl]-4-yloxy)-3-(4-fluorophenyl)propyl]-N-methyl-, ethyl ester (9CI)
(CA INDEX NAME)




RN 200004-76-8 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(1,1,3,3-tetramethylbutyl)phenoxy]propyl]-, ethyl ester (9CI)
(CA INDEX NAME)


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-81-5 CAPLUS
CN Glycine, N-methyl-N-[3-(4-phenoxyphenoxy)-3-phenylpropyl]-, ethyl ester (9CI)
(CA INDEX NAME)




RN 200004-84-8 CAPLUS
CN Glycine, N-[3-[(4'-cyano[1,1'-biphenyl]-4-yl)oxy]-3-phenylpropyl]-N-methyl-, ethyl ester (9CI)
(CA INDEX NAME)



RN 200004-87-1 CAPLUS
CN Glycine, N-methyl-N-[3-(2-naphthalenyloxy)-3-phenylpropyl]-, ethyl ester (9CI)
(CA INDEX NAME)




RN 200004-88-2 CAPLUS
CN Glycine, N-methyl-N-[3-(1-naphthalenyloxy)-3-phenylpropyl]-, ethyl ester (9CI)
(CA INDEX NAME)




RN 200004-90-6 CAPLUS

09/757,011


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
CN Glycine, N-[3-([1,1'-biphenyl]-4-yloxy)-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-96-2 CAPLUS
CN Glycine, N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 200005-05-6 CAPLUS
CN Glycine, N-[3-(4-chlorophenyl)-3-(4-cyanophenoxy)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-07-8 CAPLUS
CN Glycine, N-[3-(4-chlorophenyl)-3-phenoxypropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-08-9 CAPLUS
CN Glycine, N-[3-(4-fluorophenyl)-3-(4-methoxyphenoxy)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200005-34-1 CAPLUS
CN Glycine, N-[3,3-diphenylpropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 200005-41-0 CAPLUS
CN Glycine, N-[3-hydroxy-3-phenyl-3-(2-thienyl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 200005-42-1 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-(2-thienyl)-2-propenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-46-5 CAPLUS
CN Glycine, N-[3-(4-methoxyphenoxy)-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-49-8 CAPLUS
CN Glycine, N-[3-([4-(1,1-dimethylethyl)phenyl]thio)-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200005-11-4 CAPLUS
CN Glycine, N-methyl-N-[(3R)-3-(4-nitrophenoxy)-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 200005-17-0 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 200005-24-9 CAPLUS
CN Acetonitrile, [methyl[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino]- (9CI) (CA INDEX NAME)




RN 200005-32-9 CAPLUS
CN Phosphonic acid, [[methyl[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino]methyl]-, diethyl ester (9CI) (CA INDEX NAME)

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200005-51-2 CAPLUS
CN Glycine, N-[(3R)-3-[4-(1,1-dimethylethyl)phenoxy]-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200005-52-3 CAPLUS
CN Glycine, N-(4,4-diphenyl-3-butenyl)-N-ethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-54-5 CAPLUS
CN Glycine, N-(4,4-diphenylbutyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 200006-00-4 CAPLUS
CN Glycine, N-[3-(1-naphthalenyl)-3-phenylpropyl]-, hydrochloride (9CI) (CA INDEX NAME)

09/757,011


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



● HCl

RN 200006-07-1 CAPLUS
 CN Glycine, N-[(3S)-3-((1,1'-biphenyl)-4-yloxy)-3-(4-fluorophenyl)propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 200006-08-2 CAPLUS
 CN Glycine, N-[(3R)-3-((1,1'-biphenyl)-4-yloxy)-3-(4-fluorophenyl)propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



● HCl

RN 200006-09-3 CAPLUS
 CN Glycine, N-[(3R)-3-((1,1'-biphenyl)-4-yloxy)-3-(4-fluorophenyl)propyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




● HCl

RN 200006-10-6 CAPLUS
 CN Glycine, N-[(3R)-3-(4-fluorophenyl)-3-(4-tricyclo[3.3.1.1.3,7]dec-1-ylphenoxy)propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




● HCl

RN 200006-24-2 CAPLUS
 CN 2-Azetidinecarboxylic acid, 1-(4,4-diphenyl-3-butenyl)-, methyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200006-25-3 CAPLUS
 CN 2-Piperidinecarboxylic acid, 1-(4,4-diphenyl-3-butenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 200006-50-4 CAPLUS
 CN 2-Piperidinecarboxylic acid, 1-[3-(4-chlorophenyl)-3-(4-fluorophenyl)-3-hydroxypropyl]-, methyl ester (9CI) (CA INDEX NAME)

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



IT 76991-05-4P 200004-41-7P 200004-45-1P
 200004-46-2P 200004-47-3P 200004-48-4P
 200004-49-5P 200004-50-8P 200004-57-5P
 200004-60-0P 200004-63-3P 200004-64-4P
 200004-65-5P 200004-69-9P 200004-72-4P
 200004-83-7P 200004-85-9P 200004-86-0P
 200004-89-3P 200004-91-7P 200004-92-8P
 200004-93-9P 200004-94-0P 200004-95-1P
 200004-97-3P 200004-98-4P 200004-99-5P
 200005-00-1P 200005-01-2P 200005-02-3P
 200005-03-4P 200005-04-5P 200005-06-7P
 200005-09-0P 200005-10-3P 200005-12-5P
 200005-13-6P 200005-14-7P 200005-15-8P
 200005-16-9P 200005-18-1P 200005-19-2P
 200005-21-6P 200005-22-7P 200005-23-8P
 200005-25-0P 200005-26-1P 200005-27-2P
 200005-28-3P 200005-29-4P 200005-30-7P
 200005-31-8P 200005-33-0P 200005-35-2P
 200005-36-3P 200005-37-4P 200005-38-5P
 200005-39-6P 200005-40-9P 200005-43-2P
 200005-44-3P 200005-45-4P 200005-47-6P
 200005-48-7P 200005-50-1P 200005-53-4P
 200005-55-6P 200005-56-7P 200005-57-8P
 200005-58-9P 200005-59-0P 200005-60-3P
 200005-61-4P 200005-62-5P 200005-63-6P
 200005-64-7P 200005-65-8P 200005-66-9P
 200005-67-0P 200005-68-1P 200005-69-2P
 200005-70-3P 200005-71-6P 200005-72-7P
 200005-73-8P 200005-74-9P 200005-75-0P
 200005-76-1P 200005-77-2P 200005-78-3P
 200005-79-4P 200005-80-7P 200005-81-8P
 200005-82-9P 200005-83-0P 200005-84-1P
 200005-85-2P 200005-86-3P 200005-87-4P
 200005-88-5P 200005-89-6P 200005-90-9P
 200005-91-0P 200005-92-1P 200005-93-2P
 200005-94-3P 200005-95-4P 200005-96-5P
 200005-97-6P 200005-98-7P 200005-99-8P
 200006-01-5P 200006-02-6P 200006-03-7P
 200006-04-8P 200006-05-9P 200006-06-0P
 200006-11-7P 200006-12-8P 200006-22-0P
 200006-23-1P 200006-27-5P 200006-28-6P
 200006-29-7P 200006-30-0P 200006-31-1P
 200006-33-5P 200006-35-5P 200006-37-7P
 200006-38-9P 200006-40-2P 200006-42-4P


09/757,011

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

200006-44-6P 200006-46-8P 200006-48-0P
200006-52-6P 200006-54-8P 200006-56-0P
200006-58-2P 200006-60-6P 200006-63-3P
200006-65-5P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amino acid derivs. as pharmaceuticals for treatment of neurol. and neuropsychiatric disorders)

RN 76991-05-4 CAPLUS
CN Acetamide, 2-[(3,3-diphenylpropyl)amino]- (9CI) (CA INDEX NAME)




RN 200004-41-7 CAPLUS
CN L-Alanine, N-(4,4-diphenyl-3-butenyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 200004-45-1 CAPLUS
CN D-Alanine, N-(4,4-diphenyl-3-butenyl)-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 200004-46-2 CAPLUS
CN Glycine, N,N-bis[2-(9H-fluoren-9-yl)ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)


RN 200004-50-8 CAPLUS
CN Glycine, N-[2-(diphenylmethoxy)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 200004-57-5 CAPLUS
CN Glycine, N-[3,3-bis([1,1'-biphenyl]-4-yl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 200004-60-0 CAPLUS
CN Glycine, N,N-bis[3-(2-naphthalenyl)-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-63-3 CAPLUS
CN Glycine, N-[3-{4-[(1,1-dimethylethyl)phenyl]-3-phenylpropyl}-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-64-4 CAPLUS
CN Glycine, N-methyl-N-(3,3,3-triphenylpropyl)-, ethyl ester (9CI) (CA INDEX NAME)


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-47-3 CAPLUS
CN Glycine, N-[4,4-bis(4-fluorophenyl)butyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 200004-48-4 CAPLUS
CN Glycine, N-[3,3-bis(4-fluorophenyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-49-5 CAPLUS
CN Glycine, N-(3-cyano-3,3-diphenylpropyl)-, ethyl ester (9CI) (CA INDEX NAME)




L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-65-5 CAPLUS
CN Glycine, N,N-bis[3-{[1,1'-biphenyl]-4-yl-3-phenylpropyl}-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-69-9 CAPLUS
CN Glycine, N-(3,4-diphenyl-3-butenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 200004-72-4 CAPLUS
CN Glycine, N-[3,3-bis(4-fluorophenyl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-83-7 CAPLUS
CN Glycine, N-[3-{(4'-bromo[1,1'-biphenyl]-4-yl)oxy}-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-85-9 CAPLUS
CN Glycine, N-methyl-N-(3-phenyl-3-[3-(trifluoromethyl)phenoxy]propyl)-, ethyl ester (9CI) (CA INDEX NAME)


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-86-0 CAPLUS
CN Glycine, N-[3-phenyl-3-[3-(trifluoromethyl)phenoxy]propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 200004-89-3 CAPLUS
CN Glycine, N-methyl-N-[3-(4-methylphenoxy)-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-91-7 CAPLUS
CN Glycine, N-[3-(4-(aminosulfonyl)phenoxy)-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-92-8 CAPLUS
CN Glycine, N-methyl-N-[3-(4-nitrophenoxy)-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-98-4 CAPLUS
CN Glycine, N-[3-phenyl-3-[4-(trifluoromethoxy)phenoxy]propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 200004-99-5 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethoxy)phenoxy]propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-00-1 CAPLUS
CN Glycine, N-[3-(2,4-dimethoxyphenyl)-3-(4-(trifluoromethyl)phenoxy)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-01-2 CAPLUS
CN Glycine, N-[3-(1,3-benzodioxol-5-yloxy)-3-(4-chlorophenyl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-93-9 CAPLUS
CN Glycine, N-methyl-N-[3-[4-nitro-3-(trifluoromethyl)phenoxy]-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 200004-94-0 CAPLUS
CN Glycine, N-[3-(4-cyanophenoxy)-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-95-1 CAPLUS
CN Glycine, N-[3-(4-cyanophenoxy)-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-97-3 CAPLUS
CN Glycine, N-bis[3-phenyl-3-(4-(trifluoromethoxy)phenoxy)propyl]-, ethyl ester (9CI) (CA INDEX NAME)


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200005-02-3 CAPLUS
CN Glycine, N-[3-(4-bromophenyl)-3-phenoxypropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 200005-03-4 CAPLUS
CN Glycine, N-[3-(4-bromophenyl)-3-(4-(trifluoromethyl)phenoxy)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-04-5 CAPLUS
CN Glycine, N-[3-(4-bromophenyl)-3-(4-methoxyphenoxy)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-06-7 CAPLUS
CN Glycine, N-[3-(4-bromophenyl)-3-(4-chlorophenoxy)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



RN 200005-09-0 CAPLUS
CN Glycine, N-[3-(4-fluorophenyl)-3-phenoxypropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-10-3 CAPLUS
CN Glycine, N-[3-(4-fluorophenyl)-3-(4-(trifluoromethyl)phenoxy)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-12-5 CAPLUS
CN Glycine, N-[(3S)-3-([1,1'-biphenyl]-4-yloxy)-3-(4-fluorophenyl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)


RN 200005-16-9 CAPLUS
CN Benzenepropanamine, .gamma.-([1,1'-biphenyl]-4-yloxy)-N-(2,2-dimethoxyethyl)-4-fluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 200005-18-1 CAPLUS
CN Glycine, N-[2-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)ethyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 200005-19-2 CAPLUS
CN Glycine, N-[3-(5H-dibenzo[a,d]cyclohepten-5-yl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 200005-21-6 CAPLUS
CN Glycine, N-[3-(9,10-ethanoanthracen-9(10H)-yl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-22-7 CAPLUS

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)


RN 200005-13-6 CAPLUS
CN Glycine, N-[(3R)-3-([1,1'-biphenyl]-4-yloxy)-3-(4-fluorophenyl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 200005-14-7 CAPLUS
CN Glycine, N-[(3R)-3-([1,1'-biphenyl]-4-yloxy)-3-(4-fluorophenyl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 200005-15-8 CAPLUS
CN Glycine, N-[(3R)-3-(4-fluorophenyl)-3-(4-(tricyclo[3.3.1.1.3,7]dec-1-ylphenoxy)propyl)-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)


RN 200005-17-9 CAPLUS
CN Glycine, N-[3-(2-methoxyphenoxy)-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-23-8 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-N-propyl ester (9CI) (CA INDEX NAME)




RN 200005-25-0 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-N-phenyl ester (9CI) (CA INDEX NAME)



RN 200005-26-1 CAPLUS
CN Acetamide, N-ethyl-2-[methyl[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino]- (9CI) (CA INDEX NAME)




RN 200005-27-2 CAPLUS
CN Acetamide, N,N-diethyl-2-[methyl[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino]- (9CI) (CA INDEX NAME)




RN 200005-28-3 CAPLUS
CN Glycine, N-methyl-N-[2-methyl-3-(1-oxopropoxy)-3,4-diphenylbutyl]-N-ethyl ester (9CI) (CA INDEX NAME)


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200005-29-4 CAPLUS
CN Glycine, N-(3-hydroxy-2-methyl-3,4-diphenylbutyl)-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 200005-30-7 CAPLUS
CN Acetamide, 2-[methyl[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino]- (9CI) (CA INDEX NAME)




RN 200005-31-8 CAPLUS
CN Morpholine, 4-[[[methyl[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino]methyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 200005-33-0 CAPLUS
CN Glycine, N-[3-(1-naphthalenyl)-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, butyl ester (9CI) (CA INDEX NAME)




RN 200005-40-9 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 200005-43-2 CAPLUS
CN Glycine, N-[3-(2-furanyl)-3-hydroxy-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 200005-44-3 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-(2-thienyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-45-4 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-(phenylthio)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-47-6 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-(phenylthio)propyl]-, ethyl ester (9CI) (CA INDEX NAME)


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200005-35-2 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, 4-nitrophenyl ester (9CI) (CA INDEX NAME)




RN 200005-36-3 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 200005-37-4 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, octyl ester (9CI) (CA INDEX NAME)




RN 200005-39-5 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 200005-39-6 CAPLUS


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200005-48-7 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-50-1 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-(phenylamino)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-53-4 CAPLUS
CN Glycine, N-(3,3-diphenylpropyl)-N-methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 200005-55-6 CAPLUS
CN Glycine, N-(4,4-diphenylbutyl)-N-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 200005-56-7 CAPLUS
CN Glycine, N-(4,4-diphenylbutyl)-N-ethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 200005-57-8 CAPLUS
CN Glycine, N-(4,4-diphenyl-3-butenyl)-, hydrochloride (9CI) (CA INDEX NAME)


09/757,011

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS ON STN (Continued)




● HCl

RN 200005-59-9 CAPLUS
CN Glycine, N-(4,4-diphenylbutyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-59-0 CAPLUS
CN Glycine, N-[3-([1,1'-biphenyl]-4-yloxy)-3-(4-fluorophenyl)propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-60-3 CAPLUS
CN Glycine, N-(3-cyclohexyl-3-phenylpropyl)-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS ON STN (Continued)




● HCl

RN 200005-65-8 CAPLUS
CN Glycine, N-methyl-N-[3,3,3-tris(4-chlorophenyl)propyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 200005-66-9 CAPLUS
CN Glycine, N-methyl-N-[3-(2-naphthalenyl)-3-phenylpropyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-67-0 CAPLUS
CN Glycine, N-[3-([1,1'-biphenyl]-4-yloxy)-3-phenylpropyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS ON STN (Continued)

RN 200005-61-4 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(1,1,3,3-tetramethylbutyl)phenoxy]propyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-62-5 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(4-(trifluoromethyl)phenoxy)phenoxy]propyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 200005-63-6 CAPLUS
CN Glycine, N-[3-[4-(1,1-dimethylethyl)phenoxy]-3-phenylpropyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 200005-64-7 CAPLUS
CN Glycine, N-[3-[(4'-cyano[1,1'-biphenyl]-4-yl)oxy]-3-phenylpropyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS ON STN (Continued)




● HCl

RN 200005-68-1 CAPLUS
CN Glycine, N-[3-[4-(1,1-dimethylethyl)phenyl]-3-phenylpropyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 200005-69-2 CAPLUS
CN Glycine, N-(3-([1,1'-biphenyl]-4-yl-3-phenylpropyl)-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-70-5 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-(phenylthio)propyl]-, hydrochloride (9CI) (CA INDEX NAME)


09/757,011

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




● HCl

RN 200005-71-6 CAPLUS
CN Glycine, N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 200005-72-7 CAPLUS
CN Glycine, N-[3-(4-chlorophenyl)-3-(4-cyanophenoxy)propyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 200005-73-8 CAPLUS
CN Glycine, N-[3-(4-chlorophenyl)-3-phenoxypropyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



● HCl


RN 200005-77-2 CAPLUS
CN Glycine, N-[3-[[4-(1,1-dimethylethyl)phenyl]thio]-3-phenylpropyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 200005-78-3 CAPLUS
CN Glycine, N-[(3R)-3-([1,1'-biphenyl]-4-yloxy)-3-phenylpropyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



● HCl

RN 200005-79-4 CAPLUS
CN Glycine, N-methyl-N-[3-(4-phenoxyphenoxy)-3-phenylpropyl]-, hydrochloride (9CI) (CA INDEX NAME)


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



● HCl


RN 200005-74-9 CAPLUS
CN Glycine, N-methyl-N-[(3R)-3-(4-nitrophenoxy)-3-phenylpropyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 200005-75-0 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-76-1 CAPLUS
CN Glycine, N-[(3R)-3-[4-(1,1-dimethylethyl)phenoxy]-3-phenylpropyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




● HCl

RN 200005-80-7 CAPLUS
CN Glycine, N-[3,3-bis(4-phenoxyphenyl)propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 200005-81-8 CAPLUS
CN Glycine, N-methyl-N-[3-(1-naphthalenyloxy)-3-phenylpropyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-82-9 CAPLUS
CN Glycine, N-(3,5-diphenylpentyl)-, hydrochloride (9CI) (CA INDEX NAME)


09/757,011

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




● HCl

RN 200005-83-0 CAPLUS
CN Glycine, N-[3-(2-naphthalenyl)-3-phenylpropyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 200005-84-1 CAPLUS
CN Glycine, N-methyl-N-[3-[4-nitro-3-(trifluoromethyl)phenoxy]-3-phenylpropyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-85-2 CAPLUS
CN Glycine, N-methyl-N-(3,3,3-triphenylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

RN 200005-89-6 CAPLUS
CN Glycine, N-[3-(4-methoxyphenoxy)-3-phenylpropyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-90-9 CAPLUS
CN Glycine, N-[3-(4-fluorophenyl)-3-[4-(trifluoromethyl)phenoxy]propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 200005-91-0 CAPLUS
CN Glycine, N-methyl-N-[3-(2-naphthalenyloxy)-3-phenylpropyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 200005-92-1 CAPLUS
CN Glycine, N-[3-[4-(1,1-dimethylethyl)phenoxy]-3-(4-fluorophenyl)propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




● HCl

RN 200005-86-3 CAPLUS
CN Glycine, N-methyl-N-(3-phenoxy-3-phenylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-87-4 CAPLUS
CN Glycine, N-[3-(4-cyanophenoxy)-3-phenylpropyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-88-5 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenyl]propyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




● HCl

RN 200005-93-2 CAPLUS
CN Glycine, N-methyl-N-[3-[(6-methyl-3-pyridinyl)oxy]-3-phenylpropyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 200005-94-3 CAPLUS
CN Glycine, N-methyl-N-[3,3,3-tris(4-methoxyphenyl)propyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-95-4 CAPLUS
CN Glycine, N-[(3S)-3-[[1,1'-biphenyl]-4-yloxy]-3-phenylpropyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


09/757,011

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




● HCl

RN 200005-96-5 CAPLUS
CN Glycine, N-[3-bis(3-fluorophenyl)propyl]-N-methyl-, hydrochloride (9CI)
(CA INDEX NAME)



● HCl


RN 200005-97-6 CAPLUS
CN Glycine, N-[3-bis(3-fluorophenyl)propyl]-N-methyl-, hydrochloride (9CI)
(CA INDEX NAME)



● HCl


RN 200005-98-7 CAPLUS
CN Glycine, N-[3-bis(3-fluorophenyl)propyl]-N-methyl-, hydrochloride (9CI)
(CA INDEX NAME)

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




● HCl

RN 200006-03-7 CAPLUS
CN Glycine, N-[3-bis(3-fluorophenyl)propyl]-N-methyl-, hydrochloride (9CI)
(CA INDEX NAME)



● HCl


RN 200006-04-8 CAPLUS
CN Glycine, N-[3-bis(3-fluorophenyl)propyl]-N-methyl-, hydrochloride (9CI)
(CA INDEX NAME)



● HCl


RN 200006-05-9 CAPLUS
CN Glycine, N-[3-bis(3-fluorophenyl)propyl]-N-methyl-, hydrochloride (9CI)
(CA INDEX NAME)

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




● HCl

RN 200005-99-8 CAPLUS
CN Phosphonic acid, [[methyl[3-phenyl-3-[(4-(trifluoromethyl)phenoxy)propyl]amino]methyl]-, hydrochloride (9CI)
(CA INDEX NAME)



● HCl


RN 200006-01-5 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[(4-(trifluoromethyl)phenyl)thio]propyl]-, hydrochloride (9CI)
(CA INDEX NAME)



● HCl


RN 200006-02-6 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[(4-(trifluoromethyl)phenyl)thio]propyl]-, monohydrochloride (9CI)
(CA INDEX NAME)

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




● HCl

RN 200006-06-0 CAPLUS
CN Glycine, N-methyl-N-[3,3,3-tris(4-fluorophenyl)propyl]-, hydrochloride (9CI)
(CA INDEX NAME)



● HCl

RN 200006-11-7 CAPLUS
CN 1H-1,2,4-Triazole-3-methanamine, N-(3,3-diphenylpropyl)-N-methyl-, hydrochloride (9CI)
(CA INDEX NAME)




● x HCl



RN 200006-12-8 CAPLUS
CN Glycine, N-(3,3-diphenylpropyl)-, ethyl ester (9CI)
(CA INDEX NAME)

09/757,011


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



RN 200006-22-0 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4,4-bis(4-fluorophenyl)butyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 200006-23-1 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[2-(9H-fluoren-9-yl)ethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 200006-27-5 CAPLUS
CN L-Proline, 1-[2-(diphenylmethoxy)ethyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200006-33-3 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-2-carboxylic acid, 3-(3,3-diphenylpropyl)-, methyl ester, (1R,2R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 200006-35-5 CAPLUS
CN L-Proline, 1-(4,4-diphenyl-3-butenyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200006-37-7 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-2-carboxylic acid, 3-(4,4-diphenyl-3-butenyl)-, methyl ester, (1R,2R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 200006-39-9 CAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[2-(diphenylmethoxy)ethyl]-, methyl ester (9CI) (CA INDEX NAME)


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200006-28-6 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[2-(diphenylmethoxy)ethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 200006-29-7 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-(3,3-diphenylpropyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 200006-30-0 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 200006-31-1 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-(4,4-diphenylbutyl)-, methyl ester (9CI) (CA INDEX NAME)

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200006-40-2 CAPLUS
CN 2-Azetidinecarboxylic acid, 1-(4,4-diphenyl-3-butenyl)-, hydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 200006-42-4 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 200006-44-6 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[3,3-bis(4-fluorophenyl)propyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 200006-46-8 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-(3-hydroxy-3,3-diphenylpropyl)-, methyl ester (9CI) (CA INDEX NAME)

09/757,011


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200006-48-0 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[3-(4-chlorophenoxy)-3-phenylpropyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 200006-52-6 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[3-phenyl-3-(4-(trifluoromethyl)phenoxy)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200006-54-8 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-(3-phenoxy-3-phenylpropyl)-, ethyl ester (9CI) (CA INDEX NAME)




L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

RN 200006-85-5 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[3-(4-chlorophenyl)-3-(4-fluorophenyl)-2-propenyl]-, methyl ester (9CI) (CA INDEX NAME)




IT 101781-30-0 200004-38-2 200006-13-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of amino acid derivs. as pharmaceuticals for treatment of
neuro. and neuropsychiatric disorders)
RN 101781-30-0 CAPLUS
CN Benzeneethanol, .alpha.-[1-methyl-2-(methylamino)ethyl]-.alpha.-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 200004-38-2 CAPLUS
CN Benzene, 1,1',1''-(bromomethylidene)tris[4-fluoro- (9CI) (CA INDEX NAME)




RN 200006-13-9 CAPLUS
CN 1-Naphthalenepropanamine, .gamma.-phenyl- (9CI) (CA INDEX NAME)

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)


RN 200006-56-0 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[3-(4-methoxyphenoxy)-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200006-58-2 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[3-phenyl-3-(phenylthio)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200006-60-6 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[3-(4-chlorophenyl)-3-hydroxy-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200006-83-3 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-(4-(trifluoromethyl)phenoxy)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




IT 21763-01-9P 64723-43-9P 83584-90-1P
200003-86-7P 200003-88-9P 200003-89-0P
200003-90-3P 200003-91-4P 200003-92-5P
200003-93-6P 200003-94-7P 200003-95-8P
200003-96-9P 200003-97-0P 200003-98-1P
200003-99-2P 200004-00-6P 200004-01-9P
200004-02-0P 200004-03-1P 200004-04-2P
200004-05-3P 200004-06-4P 200004-07-5P
200004-08-6P 200004-09-7P 200004-10-0P
200004-11-1P 200004-12-2P 200004-13-3P
200004-14-4P 200004-15-5P 200004-16-6P
200004-17-7P 200004-18-8P 200004-19-9P
200004-20-2P 200004-22-4P 200004-23-5P
200004-24-6P 200004-25-7P 200004-26-8P
200004-27-9P 200004-28-0P 200004-29-1P
200004-30-4P 200004-31-5P 200004-32-6P
200004-33-7P 200004-34-8P 200004-35-9P
200004-36-0P 200004-37-1P 200006-17-3P
200006-20-8P 200006-21-9P 200006-72-0P
200006-74-2P 200006-76-4P 200006-78-6P
200006-80-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of amino acid derivs. as pharmaceuticals for treatment of
neuro. and neuropsychiatric disorders)
RN 21763-01-9 CAPLUS
CN Benzene, (3-chloro-1-phenoxypropyl)- (9CI) (CA INDEX NAME)




RN 64723-43-9 CAPLUS
CN 9H-Fluorene-9-ethanol, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



RN 83584-90-1 CAPLUS
CN Benzenepropanol, .gamma.-.gamma.-diphenyl-, 4-methylbenzenesulfonate (9CI)
(CA INDEX NAME)




RN 200003-86-7 CAPLUS
CN Benzenepropanol, 4-fluoro-.gamma.-.gamma.-bis(4-fluorophenyl)-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-88-9 CAPLUS
CN Benzenepropanol, 4-fluoro-.gamma.-.gamma.-bis(4-fluorophenyl)-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200003-92-5 CAPLUS
CN Benzenepropanol, .gamma.-phenyl-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)



RN 200003-93-6 CAPLUS
CN Benzenepropanol, 4-phenoxy-.gamma.-[1,1'-biphenyl]-4-yl-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-94-7 CAPLUS
CN [1,1'-Biphenyl]-4-propanol, .gamma.-[1,1'-biphenyl]-4-yl-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-95-8 CAPLUS
CN Benzenepropanol, 4-(1,1-dimethylethyl)-.gamma.-phenyl-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



RN 200003-89-0 CAPLUS
CN Benzenepropanol, .gamma.-cyclohexyl-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-90-3 CAPLUS
CN Benzenepropanol, 4-methoxy-.gamma.-.gamma.-bis(4-methoxyphenyl)-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-91-4 CAPLUS
CN Benzenepropanol, 3-fluoro-.gamma.-[3-fluorophenyl]-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200003-96-9 CAPLUS
CN Benzenepropanol, 4-chloro-.gamma.-.gamma.-bis(4-chlorophenyl)-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)



RN 200003-97-0 CAPLUS
CN 2-Naphthalenepropanol, .gamma.-phenyl-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-98-1 CAPLUS
CN [1,1'-Biphenyl]-4-propanol, .gamma.-phenyl-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-99-2 CAPLUS
CN 1,4-Butanediol, 1,2-diphenyl-, 4-(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

09/757,011


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-00-8 CAPLUS
CN Benzenepropanol, .gamma.-phenyl-4-(trifluoromethyl)-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200004-01-9 CAPLUS
CN Benzene, 1-[3-chloro-1-[4-(1,1-dimethylethyl)phenoxy]propyl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 200004-02-0 CAPLUS
CN Pyridine, 5-(3-chloro-1-phenylpropoxy)-2-methyl- (9CI) (CA INDEX NAME)




RN 200004-03-1 CAPLUS
CN 1,1'-Biphenyl, 4-[3-chloro-1-(4-fluorophenyl)propoxy]- (9CI) (CA INDEX NAME)




RN 200004-04-2 CAPLUS


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-09-7 CAPLUS
CN Benzene, 1-(3-chloro-1-phenylpropoxy)-4-phenoxy- (9CI) (CA INDEX NAME)




RN 200004-10-0 CAPLUS
CN 1,1'-Biphenyl, 4-bromo-4'-[3-chloro-1-(4-fluorophenyl)propoxy]- (9CI) (CA INDEX NAME)



RN 200004-11-1 CAPLUS
CN [1,1'-Biphenyl]-4-carbonitrile, 4'-(3-chloro-1-phenylpropoxy)- (9CI) (CA INDEX NAME)




RN 200004-12-2 CAPLUS
CN Benzene, 1-(3-chloro-1-phenylpropoxy)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 200004-13-3 CAPLUS
CN Naphthalene, 2-(3-chloro-1-phenylpropoxy)- (9CI) (CA INDEX NAME)

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
CN Benzene, 1-(3-chloro-1-phenylpropoxy)-4-(1,1,3,3-tetramethylbutyl)- (9CI) (CA INDEX NAME)




RN 200004-05-3 CAPLUS
CN 1,1'-Biphenyl, 4-[(1R)-3-chloro-1-phenylpropoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 200004-06-4 CAPLUS
CN 1,1'-Biphenyl, 4-[(1S)-3-chloro-1-phenylpropoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 200004-07-5 CAPLUS
CN Benzene, 1-(3-chloro-1-phenylpropoxy)-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 200004-08-6 CAPLUS
CN Benzene, 1-(3-chloro-1-phenylpropoxy)-4-(4-(trifluoromethyl)phenoxy)- (9CI) (CA INDEX NAME)


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-14-4 CAPLUS
CN Naphthalene, 1-(3-chloro-1-phenylpropoxy)- (9CI) (CA INDEX NAME)




RN 200004-15-5 CAPLUS
CN Benzene, 1-(3-chloro-1-phenylpropoxy)-4-methyl- (9CI) (CA INDEX NAME)



RN 200004-16-6 CAPLUS
CN 1,1'-Biphenyl, 4-(3-chloro-1-phenylpropoxy)- (9CI) (CA INDEX NAME)




RN 200004-17-7 CAPLUS
CN Benzenesulfonamide, 4-(3-chloro-1-phenylpropoxy)- (9CI) (CA INDEX NAME)




RN 200004-18-8 CAPLUS


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 CN Benzene, 1-(3-chloro-1-phenylpropoxy)-4-nitro- (9CI) (CA INDEX NAME)




RN 200004-19-9 CAPLUS
 CN Benzene, 4-(3-chloro-1-phenylpropoxy)-1-nitro-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 200004-20-2 CAPLUS
 CN Benzonitrile, 4-(3-chloro-1-phenylpropoxy)- (9CI) (CA INDEX NAME)




RN 200004-22-4 CAPLUS
 CN Benzene, 1-(3-chloro-1-phenylpropoxy)-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 200004-23-5 CAPLUS
 CN Benzene, 1-[3-chloro-1-[4-(trifluoromethyl)phenoxy]propyl]-2,4-dimethoxy- (9CI) (CA INDEX NAME)


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 CN Benzonitrile, 4-[3-chloro-1-(4-chlorophenyl)propoxy]- (9CI) (CA INDEX NAME)




RN 200004-29-1 CAPLUS
 CN Benzene, 1-bromo-4-[3-chloro-1-(4-chlorophenoxy)propyl]- (9CI) (CA INDEX NAME)




RN 200004-30-4 CAPLUS
 CN Benzene, 1-chloro-4-(3-chloro-1-phenoxypropyl)- (9CI) (CA INDEX NAME)



RN 200004-31-5 CAPLUS
 CN Benzene, 1-[3-chloro-1-(4-fluorophenyl)propoxy]-4-methoxy- (9CI) (CA INDEX NAME)




RN 200004-32-6 CAPLUS
 CN Benzene, 1-(3-chloro-1-phenoxypropyl)-4-fluoro- (9CI) (CA INDEX NAME)




RN 200004-33-7 CAPLUS
 CN Benzene, 1-[3-chloro-1-(4-fluorophenyl)propoxy]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-24-6 CAPLUS
 CN 1,3-Benzodioxole, 5-[3-chloro-1-(4-chlorophenyl)propoxy]- (9CI) (CA INDEX NAME)




RN 200004-25-7 CAPLUS
 CN Benzene, 1-bromo-4-(3-chloro-1-phenoxypropyl)- (9CI) (CA INDEX NAME)



RN 200004-26-8 CAPLUS
 CN Benzene, 1-bromo-4-[3-chloro-1-[4-(trifluoromethyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)




RN 200004-27-9 CAPLUS
 CN Benzene, 1-chloro-4-[3-chloro-1-(4-methoxyphenoxy)propyl]- (9CI) (CA INDEX NAME)




RN 200004-28-0 CAPLUS

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-34-8 CAPLUS
 CN Benzene, 1-[(1R)-3-chloro-1-(4-fluorophenyl)propoxy]-4-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 200004-35-9 CAPLUS
 CN 1,1'-Biphenyl, 4-[(1S)-3-chloro-1-(4-fluorophenyl)propoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 200004-36-0 CAPLUS
 CN 1,1'-Biphenyl, 4-[(1R)-3-chloro-1-(4-fluorophenyl)propoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 200004-37-1 CAPLUS
 CN Tricyclo[3.3.1.3,7]decane, 1-[4-[(1R)-3-chloro-1-(4-fluorophenyl)propoxy]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).

09/757,011


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200006-17-3 CAPLUS
CN Glycine, N-methyl-N-[[3-[(4-methylphenyl)sulfonyl]phenylamino]-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200006-20-8 CAPLUS
CN Acetonitrile, [(3,3-diphenylpropyl)amino]- (9CI) (CA INDEX NAME)




RN 200006-21-9 CAPLUS
CN Acetonitrile, [(3,3-diphenylpropyl)methylamino]- (9CI) (CA INDEX NAME)




RN 200006-72-0 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-(3-oxo-3-phenylpropyl)-, methyl ester (9CI) (CA INDEX NAME)



L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



IT 200006-19-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of amino acid derivs. as pharmaceuticals for treatment of
neuroi. and neuropsychiatric disorders)
RN 200006-19-5 CAPLUS
CN Benzenepropanaminium, N-(2-ethoxy-2-oxoethyl)-N,N-dimethyl-.gamma.-[4-(trifluoromethyl)phenoxy]-, iodide (9CI) (CA INDEX NAME)




● 1-


REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)


RN 200006-74-2 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[3-(4-fluorophenyl)-3-oxopropyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 200006-76-4 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-(3-oxo-3-phenylpropyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 200006-78-6 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-(3-hydroxy-3-phenylpropyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 200006-80-0 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-(3-chloro-3-phenylpropyl)-, methyl ester (9CI) (CA INDEX NAME)

L44 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN

DE 19840611 A1 20000309 DE 1998-19840611 19980905
CA 2343531 AA 20000316 CA 1999-2343531 19990903
WO 2000014064 A2 20000316 WO 1999-EP6486 19990903
WO 2000014064 A3 20000720
W: AU, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RU, TR, US, ZA
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
AU 9959726 A1 20000327 AU 1999-59726 19990903
EP 1109783 A2 20010627 EP 1999-968664 19990903
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
JP 2002524443 T2 20020806 JP 2000-568823 19990903
PRIORITY APPLN. INFO.: DE 1998-19840611 A 19980905
WO 1999-EP6486 W 19990903
OTHER SOURCE(S): MARPAT 132:194656
GI

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19840611	A1	20000309	DE 1998-19840611	19980905
CA 2343531	AA	20000316	CA 1999-2343531	19990903
WO 2000014064	A2	20000316	WO 1999-EP6486	19990903
WO 2000014064	A3	20000720		
W: AU, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RU, TR, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9959726	A1	20000327	AU 1999-59726	19990903
EP 1109783	A2	20010627	EP 1999-968664	19990903
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002524443	T2	20020806	JP 2000-568823	19990903
PRIORITY APPLN. INFO.: DE 1998-19840611 A 19980905				
WO 1999-EP6486 W 19990903				
OTHER SOURCE(S): MARPAT 132:194656				
GI				




AB Title compds. [I; R1-R7 = H, OH, halo, cyano, alkyl, alkenyl, alkynyl, (substituted) aryl, heteroaryl, etc.; R1R2 and/or R3R4 and/or R5R6 = (substituted) alkylidene, O; pairs of adjoining R1-R7 = double bond; X = CO2M, group physiol. convertible to CO2M; M = H, pharmaceutically acceptable cation; Z = Y3CO, Y2C:CR15, Y2C:NO; R15 = H, alkyl, halo; Y = (substituted) aryl, heteroaryl; A1 = (CR8R9)n, (substituted) alkylene, or a combination thereof; n .gtoreq.2; R8, R9 = H, alkyl, halo, OH, etc.; A2 = (CR10R11)m; R10, R11 = H, alkyl, halo; m .gtoreq.2], were prepd. as GABA uptake inhibitors (no data). Thus, L-proline Me ester hydrochloride (prepn. given), KI, K2CO3, and 4,4-diphenylbut-3-en-1-yl bromide were stirred 46 h in acetone to give 52.4% Me (S)-N-(4,4-diphenylbut-3-en-1-yl)pyrrolidine-2-carboxylate.
IT 200006-35-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

09/757,011

L44 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 (prepn. of proline derivs. and related compds. as GABA uptake inhibitors)
 RN 200006-35-5 CAPLUS
 CN L-Proline, 1-(4,4-diphenyl-3-butenyl)-, methyl ester (9CI) (CA INDEX NAME)




Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L44 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1999:106960 CAPLUS
 DOCUMENT NUMBER: 130:218300
 TITLE: Aminomethyl-substituted cyclic amines as microsomal triglyceride transfer protein inhibitors and pharmaceuticals containing them
 INVENTOR(S): Inoue, Satoshi; Hirao, Yuzo; Yokomoto, Masaharu; Tamura, Koichi; Amano, Hirotsuka; Ueda, Chikusa
 PATENT ASSIGNEE(S): Wakunaga Pharmaceutical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 22 pp.
 CODEN: JOKKAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11035555	A2	19990209	JP 1997-196899	19970723
PRIORITY APPL. INFO.:			JP 1997-196899	19970723
OTHER SOURCE(S):		MARPAT 130:218300		




AB Pharmaceuticals, useful for prevention and treatment of hyperlipemia or arteriosclerosis, contain title compds. I [R1 = COR4, SO2R4; R2 = H, (substituted) alkyl, (hetero)aryl, (hetero)alkyl; R1R2 = Q1; R3 = (substituted) (hetero)alkyl, N-arylcarbamoylalkyl, di(hetero)arylalkyl, arylcycloalkylalkyl, (hetero)arylalkanol, Q2; R4 = (substituted) (cyclo)alkyl, (hetero)aryl, (hetero)alkyl; ring Ar1 = arom. ring; Z = CHR5, CO, SO2; R5 = H, alkyl; A = single bond, CH2, (CH2)2, CH:CHO, S; R6 = H, alkyl, CO2H, (substituted) N-alkylcarbamoyl; ring Ar2, Ar3 = benzene, pyridine, thiophene, or furan ring; X = CHN7, O; R7 = H, alkyl; m = 1, 2; n = 1-3; 1 = 1-7] or their salts. 4'-Trifluoromethylbiphenyl-2-carboxylic acid (190 mg) was chlorinated by COCl2 in CHCl3-DMF, anidated with 350 mg

L44 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 N-(2,2,2-trifluoroethyl)-9-[4-(2-(aminomethyl)morpholino)butyl]-9H-fluorene-9-carboxamide (prepn. given) and Et3N in CHCl3 at room temp. for 2 h, and treated with HCl to give 120 mg N-(2,2,2-trifluoroethyl)-9-[4-(2-[(4'-(trifluoromethyl)biphenyl-2-yl]carbonylaminoethyl)morpholino]butyl]-9H-fluorene-9-carboxamide.HCl, which in vitro inhibited secretion of apoB lipoprotein from human HepG2 cells with IC50 of 0.0150 .mu.M.
 IT 200003-86-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of aminomethyl-substituted cyclic amines as microsomal triglyceride transfer protein inhibitors)
 RN 200003-86-7 CAPLUS
 CN Benzenepropanol, 4-fluoro-.gamma.-(4-fluorophenyl)-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)



L44 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1998:304147 CAPLUS
 DOCUMENT NUMBER: 128:322090
 TITLE: Catalyst systems for (co)polymerization of .alpha.-olefins
 INVENTOR(S): Sancho Royo, Jose; Munoz-Escalona Lafuente, Antonio; Pena Garcia, Begona; Martin, Marcos Carlos
 PATENT ASSIGNEE(S): Repsol Quimica S.A., Spain
 SOURCE: Eur. Pat. Appl., 12 pp.
 CODEN: EPXXEW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 839833	A2	19980506	EP 1997-500184	19971030
EP 839833	A3	19980502		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NO 9704998	A	19980504	NO 1997-4998	19971030
NO 9705007	A	19980504	NO 1997-5007	19971030
NO 9705008	A	19980504	NO 1997-5008	19971030
JP 10182716	A2	19980707	JP 1997-336262	19971030
JP 10226710	A2	19980825	JP 1997-336261	19971030
JP 3352374	B2	20021203		
JP 10226711	A2	19980825	JP 1997-336263	19971030
JP 3340064	B2	20021028		
US 5977392	A	19991102	US 1997-961349	19971030
AT 189822	E	20000315	AT 1997-500186	19971030
ES 2142140	T3	20000401	ES 1997-500186	19971030
ES 2158474	T3	20010901	ES 1997-500185	19971030
PRIORITY APPL. INFO.:			ES 1996-2302	A 19961030
OTHER SOURCE(S):		MARPAT 128:322090		



AB Compds. I [M = transition metal of Groups 3, 4-10 of the periodic table of the elements, lanthanide, actinide; X = H, halo, (un)substituted (cyclo)alkyl, aryl, etc.; L = neutral Lewis base; A = ring with delocalized .pi. electrons, that directly coordinates to the transition metal; E = BR2, CR32, SR32, GeR22; R2 = H, (un)substituted (cyclo)alkyl, aryl, etc.; R3 = R2, halo; D = O, S, PR4, etc.; R4 = H, (un)substituted (cyclo)alkyl, alkenyl, etc.; n, z = 0, 1, 2, 3] are used as catalysts for prepn. of high-mol.-wt. poly-.alpha.-olefins. Thus, polymn. of ethylene in the presence of (2-cyclopentadienyl-1-oxo-ethanediyl)titanium dichloride and methylaluminoxanes gave a polymer with intrinsic viscosity (in trichlorobenzene, 145.degree.) 3.5 dl/g.
 IT 64723-43-9
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

09/757,011

L44 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 (organometallic catalysts for prepn. of high-mol.-wt.
 poly-.alpha.-olefins)
 RN 64723-43-9 CAPLUS
 CN 9H-Fluorene-9-ethanol, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




applicants

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 128:48490
 DOCUMENT NUMBER: 128:48490
 TITLE: Preparation of amino acid derivatives as pharmaceuticals for treatment of neurological and neuropsychiatric disorders
 INVENTOR(S): Ognyanov, Vassil Iliya; Borden, Laurence; Bell, Stanley Charles; Zhang, Jing
 PATENT ASSIGNEE(S): Trophix Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 107 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9745115	A1	19971204	WO 1997-US9450	19970529
V: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, GR, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2254833	AA	19971204	CA 1997-2254833	19970529
AU 9731530	A1	19980105	AU 1997-31530	19970529
AU 730789	B2	20010315		
EP 1014966	A1	20000705	EP 1997-926871	19970529
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NZ 332780	A	20000728	NZ 1997-332780	19970529
BR 9709501	A	20001107	BR 1997-9501	19970529
CN 1327383	A	20011219	CN 1997-196821	19970529
JP 2002515037	T2	20020521	JP 1997-543034	19970529
NO 9805711	A	19981207	NO 1998-5711	19981207
PRIORITY APPLN. INFO.:			US 1996-655912	A 19960531
			US 1996-656063	A 19960531
			US 1997-808754	A 19970227
			US 1997-808755	A 19970227
			US 1997-807682	A 19970227
			US 1997-US9450	W 19970529

OTHER SOURCE(S): MARPAT 128:48490
 AB Amino acid derivs. R2R3R4R5 (R3* nCR4R4* R5 [X = N, C (R2 not present when X = N); R2 = H, alkyl, alkoxy, cyano, alkanoyl, etc.; R3 = aryl, heteroaryl, adamantyl, or nonarom. ring linked to X via a single bond, alkylene, etc.; R1 = alkylene, iminoxyethylene, etc.; R3 = H, alkyl, (un)substituted Ph or phenylalkyl, etc.; R3* = alkyl, O; n = 0, 1; R4, R4* = H, alkyl, hydroxyalkyl; R5 = (un)substituted carbamoyl, carboxy, aminosulfonyl, phosphoryl, etc.] were prepd. as pharmaceuticals for treatment of neurol. and neuropsychiatric disorders. Thus, N-(4,4-diphenyl-3-butenyl)glycine Et ester was by alkylation of glycine Et ester hydrochloride with 4-bromo-1,1-diphenyl-1-butene. Binding assays to measure interaction of compds. with the glycine site on the NMDA receptor

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 are illustrated.
 IT 200004-42-0P 200004-44-0P 200004-51-9P
 200004-52-0P 200004-53-1P 200004-54-2P
 200004-55-3P 200004-56-4P 200004-58-6P
 200004-59-7P 200004-61-1P 200004-62-2P
 200004-66-6P 200004-67-7P 200004-70-2P
 200004-71-3P 200004-73-5P 200004-74-6P
 200004-75-7P 200004-76-8P 200004-77-9P
 200004-78-0P 200004-79-1P 200004-80-4P
 200004-81-5P 200004-84-8P 200004-87-1P
 200004-88-2P 200004-90-6P 200004-96-2P
 200005-05-6P 200005-07-8P 200005-08-9P
 200005-11-4P 200005-17-0P 200005-24-9P
 200005-32-9P 200005-34-1P 200005-41-0P
 200005-42-1P 200005-46-5P 200005-49-8P
 200005-51-2P 200005-52-3P 200005-54-5P
 200006-00-4P 200006-07-1P 200006-08-2P
 200006-09-3P 200006-10-6P 200006-24-2P
 200006-25-3P 200006-30-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of amino acid derivs. as pharmaceuticals for treatment of neurol. and neuropsychiatric disorders)
 RN 200004-42-8 CAPLUS
 CN Glycine, N-(4,4-diphenyl-3-butenyl)-N-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 200004-44-0 CAPLUS
 CN Glycine, N-[2-(9H-fluoren-9-yl)ethyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-51-9 CAPLUS
 CN Glycine, N-methyl-N-[3,3,3-tris(4-fluorophenyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-52-0 CAPLUS
 CN Glycine, N-(3-cyclohexyl-3-phenylpropyl)-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-53-1 CAPLUS
 CN Glycine, N-methyl-N-[3,3,3-tris(4-methoxyphenyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-54-2 CAPLUS
 CN Glycine, N-[3-bis(3-fluorophenyl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 RN 200004-55-3 CAPLUS
 CN Glycine, N-(3,5-diphenylpentyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-56-4 CAPLUS
 CN Glycine, N-[3-bis(4-phenoxyphenyl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 200004-58-6 CAPLUS
 CN Glycine, N-[3-[4-(1,1-dimethylethyl)phenyl]-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-59-7 CAPLUS
 CN Glycine, N-methyl-N-[3,3,3-tris(4-chlorophenyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-61-1 CAPLUS


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-71-3 CAPLUS
 CN Glycine, N-[3-phenyl-3-[4-(trifluoromethyl)phenyl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 200004-73-5 CAPLUS
 CN Glycine, N-[3-[4-(1,1-dimethylethyl)phenoxy]-3-(4-fluorophenyl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-74-6 CAPLUS
 CN Glycine, N-methyl-N-[3-[(6-methyl-3-pyridinyl)oxy]-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-75-7 CAPLUS
 CN Glycine, N-[3-[(1,1'-biphenyl)-4-yloxy]-3-(4-fluorophenyl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 CN Glycine, N-methyl-N-[3-(2-naphthalenyl)-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-62-2 CAPLUS
 CN Glycine, N-[3-(2-naphthalenyl)-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 200004-66-6 CAPLUS
 CN Glycine, N-[3-[(1,1'-biphenyl)-4-yl]-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-67-7 CAPLUS
 CN Glycine, N-[3-[(1,1'-biphenyl)-4-yl]-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-70-2 CAPLUS
 CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenyl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-76-8 CAPLUS
 CN Glycine, N-methyl-N-[3-phenyl-3-[4-(1,1,3,3-tetramethylbutyl)phenoxy]propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-77-9 CAPLUS
 CN Glycine, N-[(3R)-3-[(1,1'-biphenyl)-4-yloxy]-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 200004-78-0 CAPLUS
 CN Glycine, N-[(3S)-3-[(1,1'-biphenyl)-4-yloxy]-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).




RN 200004-79-1 CAPLUS
 CN Glycine, N-[3-[4-(1,1-dimethylethyl)phenoxy]-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)

09/757,011


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-80-4 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(4-(trifluoromethyl)phenoxy)phenoxy]propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-81-5 CAPLUS
CN Glycine, N-methyl-N-[3-(4-phenoxyphenoxy)-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-84-8 CAPLUS
CN Glycine, N-[3-[(4'-cyano[1,1'-biphenyl]-4-yl)oxy]-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-87-1 CAPLUS
CN Glycine, N-methyl-N-[3-(2-naphthalenyloxy)-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)



L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200005-08-9 CAPLUS
CN Glycine, N-methyl-N-[3-(4-fluorophenyl)-3-(4-methoxyphenoxy)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-11-4 CAPLUS
CN Glycine, N-methyl-N-[3-(3R)-3-(4-nitrophenoxy)-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 200005-17-0 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 200005-24-9 CAPLUS
CN Acetonitrile, [methyl[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino]- (9CI) (CA INDEX NAME)

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)


RN 200004-88-2 CAPLUS
CN Glycine, N-methyl-N-[3-(1-naphthalenyloxy)-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-90-6 CAPLUS
CN Glycine, N-[3-[(1,1'-biphenyl)-4-yloxy]-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 200004-96-2 CAPLUS
CN Glycine, N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-05-6 CAPLUS
CN Glycine, N-[3-(4-chlorophenyl)-3-(4-cyanophenoxy)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-07-8 CAPLUS
CN Glycine, N-[3-(4-chlorophenyl)-3-phenoxypropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200005-32-9 CAPLUS
CN Phosphonic acid, [[methyl[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino]methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 200005-34-1 CAPLUS
CN Glycine, N-(3,3-diphenylpropyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 200005-41-0 CAPLUS
CN Glycine, N-[3-hydroxy-3-phenyl-3-(2-thienyl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-42-1 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-(2-thienyl)-2-propenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-46-5 CAPLUS
CN Glycine, N-[3-(4-methoxyphenoxy)-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)

09/757,011

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200005-49-8 CAPLUS
CN Glycine, N-[3-[(1,1-dimethylethyl)phenyl]thio]-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-51-2 CAPLUS
CN Glycine, N-[(3R)-3-[4-(1,1-dimethylethyl)phenoxy]-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 200005-52-3 CAPLUS
CN Glycine, N-(4,4-diphenyl-3-butenyl)-N-ethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 200005-54-5 CAPLUS
CN Glycine, N-(4,4-diphenylbutyl)-, ethyl ester (9CI) (CA INDEX NAME)




L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



● HCl

RN 200006-09-3 CAPLUS
CN Glycine, N-[(3R)-3-[(1,1'-biphenyl]-4-yloxy)-3-(4-fluorophenyl)propyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




● HCl

RN 200006-10-6 CAPLUS
CN Glycine, N-[(3R)-3-(4-fluorophenyl)-3-(4-tricyclo[3.3.1.1.3,7]dec-1-ylphenoxy)propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)


RN 200006-00-4 CAPLUS
CN Glycine, N-[3-(1-naphthalenyl)-3-phenylpropyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 200006-07-1 CAPLUS
CN Glycine, N-[(3S)-3-[(1,1'-biphenyl]-4-yloxy)-3-(4-fluorophenyl)propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 200006-08-2 CAPLUS
CN Glycine, N-[(3R)-3-[(1,1'-biphenyl)-4-yloxy]-3-(4-fluorophenyl)propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




● HCl

RN 200006-24-2 CAPLUS
CN 2-Azetidinecarboxylic acid, 1-(4,4-diphenyl-3-butenyl)-, methyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200006-25-3 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-(4,4-diphenyl-3-butenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 200006-50-4 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[3-(4-chlorophenyl)-3-(4-fluorophenyl)-3-hydroxypropyl]-, methyl ester (9CI) (CA INDEX NAME)

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




```


IT
76991-05-46 200004-41-79 200004-45-18
200004-46-29 200004-47-39 200004-48-49
200004-49-59 200004-50-89 200004-57-59
200004-60-09 200004-63-39 200004-64-49
200004-65-75 200004-69-59 200004-72-49
200004-63-59 200004-85-99 200004-86-09
200004-89-39 200004-91-79 200004-92-89
200004-93-29 200004-94-09 200004-95-19
200004-96-39 200004-97-09 200004-98-59
200005-00-19 200005-01-29 200005-02-79
200005-03-09 200005-04-29 200005-06-79
200005-09-09 200005-10-39 200005-12-59
200005-13-69 200005-14-79 200005-15-89
200005-16-99 200005-18-19 200005-19-29
200005-21-69 200005-22-79 200005-23-89
200005-25-09 200005-26-19 200005-27-29
200005-28-39 200005-29-49 200005-30-79
200005-31-99 200005-32-09 200005-33-29
200005-36-39 200005-37-49 200005-38-59
200005-39-69 200005-40-99 200005-43-29
200005-44-39 200005-45-49 200005-47-69
200005-48-79 200005-50-19 200005-53-49
200005-55-69 200005-56-79 200005-57-89
200005-58-99 200005-59-09 200005-60-39
200005-61-49 200005-62-59 200005-63-69
200005-64-79 200005-65-69 200005-66-99
200005-67-09 200005-68-19 200005-69-29
200005-70-59 200005-71-69 200005-72-79
200005-73-89 200005-74-99 200005-75-09
200005-76-19 200005-77-29 200005-78-39
200005-79-49 200005-80-79 200005-81-89
200005-82-99 200005-83-09 200005-84-19
200005-85-29 200005-86-39 200005-87-49
200005-88-59 200005-89-69 200005-90-99
200005-91-09 200005-92-19 200005-93-29
200005-94-39 200005-95-49 200005-96-59
200005-97-69 200005-98-79 200005-99-89
200006-01-09 200006-02-69 200006-03-09
200006-04-09 200006-05-09 200006-06-09
200006-11-79 200006-12-89 200006-22-09

```


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-47-3 CAPLUS
CN Glycine, N-[4,4-bis(4-fluorophenyl)butyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 200004-48-4 CAPLUS
CN Glycine, N-[3,3-bis(4-fluorophenyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 200004-49-5 CAPLUS
CN Glycine, N-(3-cyano-3,3-diphenylpropyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-50-8 CAPLUS
CN Glycine, N-[2-(diphenylmethoxy)ethyl]-, methyl ester (9CI) (CA INDEX)

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

200006-29-7P 200006-30-0P 200006-31-1P
200006-33-3P 200006-35-5P 200006-37-7P
200006-39-9P 200006-40-2P 200006-42-4P
200006-44-6P 200006-46-8P 200006-48-0P
200006-52-6P 200006-54-8P 200006-56-0P
200006-58-2P 200006-60-6P 200006-83-3P
200006-85-5P


200008-05-3F
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of amino acid derivs. as pharmaceuticals for treatment of neurol. and neuropsychiatric disorders)

RN	76991-05-4	CAPLUS	
CN	Acetamide, 2-[(3,3-diphenylpropyl)amino]- (9CI)	(CA INDEX NAME)	




RN 200004-41-7 CAPLUS
CN L-Alanine, N-(4,4-diphenyl-3-butenyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200004-45-1 CAPLUS
CN D-Alanine, N-(4,4-diphenyl-3-butenyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200004-46-2 CAPLUS
CN Glycine, N,N-bis[2-(9H-fluoren-9-yl)ethyl]-, ethyl ester (9CI) (CA INDEX
NAME)


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-57-5 CAPLUS
CN Glycine, N-[3,3-bis([1,1'-biphenyl]-4-yl)propyl]-N-methyl-, ethyl ester
(9CI) (CA INDEX NAME)




RN 200004-60-0 CAPLUS
CN Glycine, N,N-bis[3-(2-naphthalenyl)-3-phenylpropyl]-, ethyl ester (9CI)
(CA INDEX NAME)



RN 200004-63-3 CAPLUS
CN Glycine, N-[3-(4-(1,1-dimethylethyl)phenyl)-3-phenylpropyl]-, ethyl ester
(9CI) (CA INDEX NAME)




RN 200004-64-4 CAPLUS
CN Glycine, N-methyl-N-(3,3,3-triphenylpropyl)-, ethyl ester (9CI) (CA INDEX NAME)




09/757,011


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 RN 200004-65-5 CAPLUS
 CN Glycine, N,N-bis[3-[(1,1'-biphenyl)-4-yl]-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-69-9 CAPLUS
 CN Glycine, N-(3,4-diphenyl-3-butenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 200004-72-4 CAPLUS
 CN Glycine, N-[3,3-bis(4-fluorophenyl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-83-7 CAPLUS
 CN Glycine, N-[3-{[4'-bromo(1,1'-biphenyl)-4-yl]oxy}-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-85-9 CAPLUS
 CN Glycine, N-methyl-N-[3-phenyl-3-[3-(trifluoromethyl)phenoxy]propyl]-, ethyl ester (9CI) (CA INDEX NAME)


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-93-9 CAPLUS
 CN Glycine, N-methyl-N-[3-[4-nitro-3-(trifluoromethyl)phenoxy]-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-94-0 CAPLUS
 CN Glycine, N-[3-(4-cyanophenoxy)-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 200004-95-1 CAPLUS
 CN Glycine, N-(3-phenoxy-3-phenylpropyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-97-3 CAPLUS
 CN Glycine, N,N-bis[3-phenyl-3-(4-(trifluoromethoxy)phenoxy)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-98-4 CAPLUS
 CN Glycine, N-[3-phenyl-3-[4-(trifluoromethoxy)phenoxy]propyl]-, ethyl ester


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-86-0 CAPLUS
 CN Glycine, N-[3-phenyl-3-[3-(trifluoromethyl)phenoxy]propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 200004-89-3 CAPLUS
 CN Glycine, N-methyl-N-[3-(4-methylphenoxy)-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-91-7 CAPLUS
 CN Glycine, N-[3-[4-(aminosulfonyl)phenoxy]-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-92-8 CAPLUS
 CN Glycine, N-methyl-N-[3-(4-nitrophenoxy)-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-99-5 CAPLUS
 CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethoxy)phenoxy]propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 200005-00-1 CAPLUS
 CN Glycine, N-[3-(2,4-dimethoxyphenyl)-3-[4-(trifluoromethyl)phenoxy]propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-01-2 CAPLUS
 CN Glycine, N-[3-(1,3-benzodioxol-5-yl)oxy]-3-(4-chlorophenyl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-02-3 CAPLUS
 CN Glycine, N-[3-(4-bromophenyl)-3-phenoxypropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200005-03-4 CAPLUS
CN Glycine, N-[3-(4-bromophenyl)-3-(4-(trifluoromethyl)phenoxy)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 200005-04-5 CAPLUS
CN Glycine, N-[3-(4-chlorophenyl)-3-(4-methoxyphenoxy)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-06-7 CAPLUS
CN Glycine, N-[3-(4-bromophenyl)-3-(4-chlorophenoxy)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-09-0 CAPLUS
CN Glycine, N-[3-(4-fluorophenyl)-3-phenoxypropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200005-14-7 CAPLUS
CN Glycine, N-[3-(4-fluorophenyl)-3-(4-(trifluoromethyl)phenoxy)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 200005-15-8 CAPLUS
CN Glycine, N-[3-(4-fluorophenyl)-3-(4-(trifluoromethyl)phenoxy)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 200005-16-9 CAPLUS
CN Benzeneprapanamine, .gamma.-([1,1'-biphenyl]-4-yloxy)-N-(2,2-dimethoxyethyl)-4-fluoro-N-methyl- (9CI) (CA INDEX NAME)

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200005-10-3 CAPLUS
CN Glycine, N-[3-(4-fluorophenyl)-3-(4-(trifluoromethyl)phenoxy)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 200005-12-5 CAPLUS
CN Glycine, N-[3-(4-fluorophenyl)-3-(4-(trifluoromethyl)phenoxy)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).




RN 200005-13-6 CAPLUS
CN Glycine, N-[3-(4-fluorophenyl)-3-(4-(trifluoromethyl)phenoxy)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200005-18-1 CAPLUS
CN Glycine, N-[2-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)ethyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 200005-19-2 CAPLUS
CN Glycine, N-[3-(4-fluorophenyl)-3-(4-(trifluoromethyl)phenoxy)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-21-6 CAPLUS
CN Glycine, N-[3-(4-fluorophenyl)-3-(4-(trifluoromethyl)phenoxy)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-22-7 CAPLUS
CN Glycine, N-[3-(4-fluorophenyl)-3-(4-(trifluoromethyl)phenoxy)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)

09/757,011


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200005-23-8 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, propyl ester (9CI) (CA INDEX NAME)




RN 200005-25-0 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 200005-26-1 CAPLUS
CN Acetamide, N-ethyl-2-[methyl[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino]- (9CI) (CA INDEX NAME)




RN 200005-27-2 CAPLUS
CN Acetamide, N,N-diethyl-2-[methyl[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino]- (9CI) (CA INDEX NAME)




RN 200005-28-3 CAPLUS
CN Glycine, N-methyl-N-[2-methyl-3-(1-oxopropoxy)-3,4-diphenylbutyl]-, ethyl ester (9CI) (CA INDEX NAME)


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200005-35-2 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, 4-nitrophenyl ester (9CI) (CA INDEX NAME)




RN 200005-36-3 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 200005-37-4 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, octyl ester (9CI) (CA INDEX NAME)




RN 200005-38-5 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 200005-39-6 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, butyl ester (9CI) (CA INDEX NAME)


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200005-29-4 CAPLUS
CN Glycine, N-(3-hydroxy-2-methyl-3,4-diphenylbutyl)-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 200005-30-7 CAPLUS
CN Acetamide, 2-[methyl[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino]- (9CI) (CA INDEX NAME)




RN 200005-31-8 CAPLUS
CN Morpholine, 4-[[methyl[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino]methyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 200005-33-0 CAPLUS
CN Glycine, N-[3-(1-naphthalenyl)-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200005-40-9 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 200005-43-2 CAPLUS
CN Glycine, N-[3-(2-furanyl)-3-hydroxy-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-44-3 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-(2-thienyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 200005-45-4 CAPLUS
CN Glycine, N-methyl-N-(3-phenoxy-3-phenylpropyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-47-6 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-(phenylthio)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)


RN 200005-48-7 CAPLUS
 CN Glycine, N-methyl-N-[3-phenyl-3-[[4-(trifluoromethyl)phenyl]thio]propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-50-1 CAPLUS
 CN Glycine, N-methyl-N-[3-phenyl-3-(phenylamino)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-53-4 CAPLUS
 CN Glycine, N-(3,3-diphenylpropyl)-N-methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 200005-55-6 CAPLUS
 CN Glycine, N-(4,4-diphenylbutyl)-N-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 200005-56-7 CAPLUS
 CN Glycine, N-(4,4-diphenylbutyl)-N-ethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 200005-57-8 CAPLUS
 CN Glycine, N-(4,4-diphenyl-3-butenyl)-, hydrochloride (9CI) (CA INDEX NAME)


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

RN 200005-61-4 CAPLUS
 CN Glycine, N-methyl-N-[3-phenyl-3-[4-(1,1,3,3-tetramethylbutyl)phenoxy]propyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-62-5 CAPLUS
 CN Glycine, N-methyl-N-[3-phenyl-3-[4-[4-(trifluoromethyl)phenoxy]phenoxy]propyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 200005-63-6 CAPLUS
 CN Glycine, N-[3-[4-(1,1-dimethylethyl)phenoxy]-3-phenylpropyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 200005-64-7 CAPLUS
 CN Glycine, N-[3-[4-(4'-cyano[1,1'-biphenyl]-4-yl)oxy]-3-phenylpropyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




● HCl

RN 200005-58-9 CAPLUS
 CN Glycine, N-(4,4-diphenylbutyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-59-0 CAPLUS
 CN Glycine, N-[3-([1,1'-biphenyl]-4-yloxy)-3-(4-fluorophenyl)propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-60-3 CAPLUS
 CN Glycine, N-(3-cyclohexyl-3-phenylpropyl)-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




● HCl

RN 200005-65-8 CAPLUS
 CN Glycine, N-methyl-N-[3,3,3-tris(4-chlorophenyl)propyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 200005-66-9 CAPLUS
 CN Glycine, N-methyl-N-[3-(2-naphthalenyl)-3-phenylpropyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-67-0 CAPLUS
 CN Glycine, N-[3-([1,1'-biphenyl]-4-yloxy)-3-phenylpropyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)


09/757,011

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS ON STN (Continued)




● HCl

RN 200005-68-1 CAPLUS
CN Glycine, N-[3-[4-(1,1-dimethylethyl)phenyl]-3-phenylpropyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 200005-69-2 CAPLUS
CN Glycine, N-[3-[1,1'-biphenyl]-4-yl-3-phenylpropyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 200005-70-5 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-(phenylthio)propyl]-, hydrochloride (9CI) (CA INDEX NAME)


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS ON STN (Continued)



● HCl


RN 200005-74-9 CAPLUS
CN Glycine, N-methyl-N-[(3R)-3-(4-nitrophenoxy)-3-phenylpropyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 200005-75-0 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-76-1 CAPLUS
CN Glycine, N-[(3R)-3-[4-(1,1-dimethylethyl)phenoxy]-3-phenylpropyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS ON STN (Continued)




● HCl

RN 200005-71-6 CAPLUS
CN Glycine, N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 200005-72-7 CAPLUS
CN Glycine, N-[3-(4-chlorophenyl)-3-(4-cyanophenoxy)propyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 200005-73-8 CAPLUS
CN Glycine, N-[3-(4-chlorophenyl)-3-phenoxypropyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS ON STN (Continued)



● HCl


RN 200005-77-2 CAPLUS
CN Glycine, N-[3-[[4-(1,1-dimethylethyl)phenyl]thio]-3-phenylpropyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 200005-78-3 CAPLUS
CN Glycine, N-[(3R)-3-[[1,1'-biphenyl]-4-yloxy]-3-phenylpropyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 200005-79-4 CAPLUS
CN Glycine, N-methyl-N-[3-(4-phenoxyphenoxy)-3-phenylpropyl]-, hydrochloride (9CI) (CA INDEX NAME)


09/757,011

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




● HCl

RN 200005-80-7 CAPLUS
CN Glycine, N-methyl-N-[3-(4-phenoxyphenyl)propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 200005-81-8 CAPLUS
CN Glycine, N-methyl-N-[3-(1-naphthalenyloxy)-3-phenylpropyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 200005-82-9 CAPLUS
CN Glycine, N-(3,5-diphenylpentyl)-, hydrochloride (9CI) (CA INDEX NAME)

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




● HCl

RN 200005-86-3 CAPLUS
CN Glycine, N-methyl-N-(3-phenoxy-3-phenylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-87-4 CAPLUS
CN Glycine, N-[3-(4-cyanophenoxy)-3-phenylpropyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 200005-88-5 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-(4-(trifluoromethyl)phenyl)propyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 200005-89-6 CAPLUS
CN Glycine, N-[3-(4-methoxyphenoxy)-3-phenylpropyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




● HCl

RN 200005-83-0 CAPLUS
CN Glycine, N-[3-(2-naphthalenyl)-3-phenylpropyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 200005-84-1 CAPLUS
CN Glycine, N-methyl-N-[3-[4-nitro-3-(trifluoromethyl)phenoxy]-3-phenylpropyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 200005-85-2 CAPLUS
CN Glycine, N-methyl-N-(3,3,3-triphenylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




● HCl

RN 200005-90-9 CAPLUS
CN Glycine, N-[3-(4-fluorophenyl)-3-[4-(trifluoromethyl)phenoxy]propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 200005-91-0 CAPLUS
CN Glycine, N-methyl-N-[3-(2-naphthalenyloxy)-3-phenylpropyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-92-1 CAPLUS
CN Glycine, N-[3-[4-(1,1-dimethylethyl)phenoxy]-3-(4-fluorophenyl)propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)


09/757,011

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




● HCl

RN 200005-93-2 CAPLUS
CN Glycine, N-methyl-N-[3-((6-methyl-3-pyridinyl)oxy)-3-phenylpropyl]-, hydrochloride (9C1) (CA INDEX NAME)



● x HCl

RN 200005-94-3 CAPLUS
CN Glycine, N-methyl-N-[3,3-bis(4-methoxyphenyl)propyl]-, hydrochloride (9C1) (CA INDEX NAME)




● HCl

RN 200005-95-4 CAPLUS


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

RN 200005-98-7 CAPLUS
CN Glycine, N-[3-[[4-(1,1-dimethylethyl)phenyl]-3-phenylpropyl]-N-methyl-, hydrochloride (9C1) (CA INDEX NAME)




● HCl

RN 200005-99-8 CAPLUS
CN Phosphonic acid, [(methyl[3-phenyl-3-[[4-(trifluoromethyl)phenoxy]propyl]amino]methyl]-, hydrochloride (9C1) (CA INDEX NAME)



● HCl

RN 200006-01-5 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[[4-(trifluoromethyl)phenyl]thio]propyl]-, hydrochloride (9C1) (CA INDEX NAME)




● HCl

RN 200006-02-6 CAPLUS
CN Glycine, N-methyl-N-[3-(4-nitrophenyl)-3-phenylpropyl]-, monohydrochloride (9C1) (CA INDEX NAME)


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
CN Glycine, N-[(3S)-3-[[1,1'-biphenyl]-4-yloxy]-3-phenylpropyl]-N-methyl-, hydrochloride (9C1) (CA INDEX NAME)

Absolute stereochemistry. Rotation (*).




● HCl

RN 200005-96-5 CAPLUS
CN Glycine, N-[3-bis(3-fluorophenyl)propyl]-N-methyl-, hydrochloride (9C1) (CA INDEX NAME)




● HCl

RN 200005-97-6 CAPLUS
CN Glycine, N-[3-bis(1,1'-biphenyl)-4-yl]propyl]-N-methyl-, hydrochloride (9C1) (CA INDEX NAME)




● HCl

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




● HCl

RN 200006-03-7 CAPLUS
CN Glycine, N-[3-bis(1,1'-biphenyl)-4-yl-3-phenylpropyl]-, hydrochloride (9C1) (CA INDEX NAME)



● HCl

RN 200006-04-8 CAPLUS
CN Glycine, N-[3-phenyl-3-[[4-(trifluoromethyl)phenyl]thio]propyl]-, hydrochloride (9C1) (CA INDEX NAME)




● HCl

RN 200006-05-9 CAPLUS
CN Glycine, N-[3-(4-fluorophenyl)-3-(4-methoxyphenoxy)propyl]-N-methyl-, hydrochloride (9C1) (CA INDEX NAME)


09/757,011

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




● HCl

RN 200006-06-0 CAPLUS
CN Glycine, N-methyl-N-(3,3,3-tris(4-fluorophenyl)propyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 200006-11-7 CAPLUS
CN 1H-1,2,4-Triazole-3-methanamine, N-(3,3-diphenylpropyl)-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 200006-12-8 CAPLUS


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200006-28-6 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[2-(diphenylmethoxy)ethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 200006-29-7 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-(3,3-diphenylpropyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 200006-30-0 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-, methyl ester (9CI) (CA INDEX NAME)





RN 200006-31-1 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-(4,4-diphenylbutyl)-, methyl ester (9CI) (CA INDEX NAME)


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
CN Glycine, N-(3,3-diphenylpropyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 200006-22-0 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[4,4-bis(4-fluorophenyl)butyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 200006-23-1 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[2-(9H-fluoren-9-yl)ethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 200006-27-5 CAPLUS
CN L-Proline, 1-[2-(diphenylmethoxy)ethyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200006-33-3 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-2-carboxylic acid, 3-(3,3-diphenylpropyl)-, methyl ester, (1R,2R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 200006-35-5 CAPLUS
CN L-Proline, 1-(4,4-diphenyl-3-butenyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 200006-37-7 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-2-carboxylic acid, 3-(4,4-diphenyl-3-butenyl)-, methyl ester, (1R,2R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 200006-39-9 CAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[2-(diphenylmethoxy)ethyl]-, methyl ester (9CI) (CA INDEX NAME)


09/757,011

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200006-40-2 CAPLUS
CN 2-Azetidinyl-1-(4-(4-diphenyl-3-butenyl)-, hydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl


RN 200006-42-4 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 200006-44-6 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[3-bis(4-fluorophenyl)propyl]-, methyl ester (9CI) (CA INDEX NAME)




L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200006-56-0 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[3-(4-methoxyphenoxy)-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 200006-58-2 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[3-phenyl-3-(phenylthio)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200006-60-6 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[3-(4-chlorophenyl)-3-hydroxy-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200006-83-3 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, ethyl ester (9CI) (CA INDEX NAME)

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)


RN 200006-46-8 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-(3-hydroxy-3,3-diphenylpropyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 200006-48-0 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[3-(4-chlorophenoxy)-3-phenylpropyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 200006-52-6 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200006-54-8 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-(3-phenoxy-3-phenylpropyl)-, ethyl ester (9CI) (CA INDEX NAME)


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



RN 200006-85-5 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[3-(4-chlorophenyl)-3-(4-fluorophenyl)-2-propenyl]-, methyl ester (9CI) (CA INDEX NAME)




IT 101781-30-0 200004-38-2 200006-13-9
RL: RCT (Reactant), RACT (Reactant or reagent)
(prepn. of amino acid derivs. as pharmaceuticals for treatment of neurol. and neuropsychiatric disorders)
RN 101781-30-0 CAPLUS
CN Benzeneethanol, .alpha.-[1-methyl-2-(methylamino)ethyl]-.alpha.-phenyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200004-38-2 CAPLUS
CN Benzene, 1,1',1''-(bromomethylidene)tris[4-fluoro- (9CI) (CA INDEX NAME)




RN 200006-13-9 CAPLUS

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
CN 1-Naphthalenepropanamine, .gamma.-phenyl- (9CI) (CA INDEX NAME)




IT 21763-01-9P 64723-43-9P 83584-90-1P
200003-86-7P 200003-88-9P 200003-89-0P
200003-90-3P 200003-91-4P 200003-92-5P
200003-93-6P 200003-94-7P 200003-95-8P
200003-96-9P 200003-97-0P 200003-98-1P
200003-99-2P 200004-00-8P 200004-01-9P
200004-02-0P 200004-03-1P 200004-04-2P
200004-05-3P 200004-06-4P 200004-07-5P
200004-08-6P 200004-09-7P 200004-10-0P
200004-11-1P 200004-12-2P 200004-13-3P
200004-14-4P 200004-15-5P 200004-16-6P
200004-17-7P 200004-18-8P 200004-19-9P
200004-20-2P 200004-22-4P 200004-23-5P
200004-24-6P 200004-25-7P 200004-26-8P
200004-27-9P 200004-28-0P 200004-29-1P
200004-30-4P 200004-31-5P 200004-32-6P
200004-33-7P 200004-34-8P 200004-35-9P
200004-36-0P 200004-37-1P 200006-17-3P
200006-20-8P 200006-21-9P 200006-72-0P
200006-74-2P 200006-76-4P 200006-78-6P
200006-80-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of amino acid derivs. as pharmaceuticals for treatment of neurol. and neuropsychiatric disorders)
RN 21763-01-9 CAPLUS
CN Benzene, (3-chloro-1-phenoxypropyl)- (9CI) (CA INDEX NAME)




RN 64723-43-9 CAPLUS
CN 9H-Fluorene-9-ethanol, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



RN 200003-89-0 CAPLUS
CN Benzenepropanol, .gamma.-cyclohexyl-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-90-3 CAPLUS
CN Benzenepropanol, 4-methoxy-.gamma.-.gamma.-bis(4-methoxyphenyl)-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-91-4 CAPLUS
CN Benzenepropanol, 3-fluoro-.gamma.-.gamma.-bis(4-fluorophenyl)-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



RN 83584-90-1 CAPLUS
CN Benzenepropanol, .gamma.-.gamma.-diphenyl-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-86-7 CAPLUS
CN Benzenepropanol, 4-fluoro-.gamma.-.gamma.-bis(4-fluorophenyl)-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-88-9 CAPLUS
CN Benzenepropanol, 4-fluoro-.gamma.-.gamma.-bis(4-fluorophenyl)-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200003-92-5 CAPLUS
CN Benzenepentanol, .gamma.-phenyl-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)



RN 200003-93-6 CAPLUS
CN Benzenepropanol, 4-phenoxy-.gamma.-.gamma.-bis(4-phenoxyphenyl)-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-94-7 CAPLUS
CN [1,1'-Biphenyl]-4-propanol, .gamma.-[1,1'-biphenyl]-4-yl-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-95-8 CAPLUS
CN Benzenepropanol, 4-(1,1-dimethylethyl)-.gamma.-phenyl-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200003-96-9 CAPLUS
CN Benzenepropanol, 4-chloro-.gamma.,.gamma.-bis(4-chlorophenyl)-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)



RN 200003-97-0 CAPLUS
CN 2-Naphthalenepropanol, .gamma.-phenyl-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-98-1 CAPLUS
CN [1,1'-Biphenyl]-4-propanol, .gamma.-phenyl-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-99-2 CAPLUS

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-04-2 CAPLUS
CN Benzene, 1-(3-chloro-1-phenylpropoxy)-4-[(1,1,3,3-tetramethylbutyl)- (9CI) (CA INDEX NAME)




RN 200004-05-3 CAPLUS
CN 1,1'-Biphenyl, 4-[(1R)-3-chloro-1-phenylpropoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 200004-06-4 CAPLUS
CN 1,1'-Biphenyl, 4-[(1S)-3-chloro-1-phenylpropoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 200004-07-5 CAPLUS
CN Benzene, 1-(3-chloro-1-phenylpropoxy)-4-[(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 200004-08-6 CAPLUS
CN Benzene, 1-(3-chloro-1-phenylpropoxy)-4-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
CN 1,4-Butanediol, 1,2-diphenyl-, 4-(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)




RN 200004-00-8 CAPLUS
CN Benzenepropanol, .gamma.-phenyl-4-(trifluoromethyl)-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)



RN 200004-01-9 CAPLUS
CN Benzene, 1-[3-chloro-1-[4-(1,1-dimethylethyl)phenoxy]propyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 200004-02-0 CAPLUS
CN Pyridine, 5-(3-chloro-1-phenylpropoxy)-2-methyl- (9CI) (CA INDEX NAME)




RN 200004-03-1 CAPLUS
CN 1,1'-Biphenyl, 4-[3-chloro-1-(4-fluorophenyl)propoxy]- (9CI) (CA INDEX NAME)


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-09-7 CAPLUS
CN Benzene, 1-(3-chloro-1-phenylpropoxy)-4-phenoxy- (9CI) (CA INDEX NAME)




RN 200004-10-0 CAPLUS
CN 1,1'-Biphenyl, 4-bromo-4'-[3-chloro-1-(4-fluorophenyl)propoxy]- (9CI) (CA INDEX NAME)



RN 200004-11-1 CAPLUS
CN [1,1'-Biphenyl]-4-carbonitrile, 4'-(3-chloro-1-phenylpropoxy)- (9CI) (CA INDEX NAME)




RN 200004-12-2 CAPLUS
CN Benzene, 1-(3-chloro-1-phenylpropoxy)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 200004-13-3 CAPLUS
CN Naphthalene, 2-(3-chloro-1-phenylpropoxy)- (9CI) (CA INDEX NAME)


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-14-4 CAPLUS
CN Naphthalene, 1-(3-chloro-1-phenylpropoxy)- (9CI) (CA INDEX NAME)



RN 200004-15-5 CAPLUS
CN Benzene, 1-(3-chloro-1-phenylpropoxy)-4-methyl- (9CI) (CA INDEX NAME)




RN 200004-16-6 CAPLUS
CN 1,1'-Biphenyl, 4-(3-chloro-1-phenylpropoxy)- (9CI) (CA INDEX NAME)




RN 200004-17-7 CAPLUS
CN Benzenesulfonamide, 4-(3-chloro-1-phenylpropoxy)- (9CI) (CA INDEX NAME)


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-23-5 CAPLUS
CN Benzene, 1-[3-chloro-1-{4-(trifluoromethyl)phenoxy}propyl]-2,4-dimethoxy- (9CI) (CA INDEX NAME)




RN 200004-24-6 CAPLUS
CN 1,3-Benzodioxole, 5-[3-chloro-1-(4-chlorophenyl)propoxy]- (9CI) (CA INDEX NAME)



RN 200004-25-7 CAPLUS
CN Benzene, 1-bromo-4-(3-chloro-1-phenoxypropyl)- (9CI) (CA INDEX NAME)




RN 200004-26-8 CAPLUS
CN Benzene, 1-bromo-4-[3-chloro-1-{4-(trifluoromethyl)phenoxy}propyl]- (9CI) (CA INDEX NAME)




RN 200004-27-9 CAPLUS
CN Benzene, 1-chloro-4-[3-chloro-1-(4-methoxyphenoxy)propyl]- (9CI) (CA INDEX NAME)


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-18-8 CAPLUS
CN Benzene, 1-(3-chloro-1-phenylpropoxy)-4-nitro- (9CI) (CA INDEX NAME)



RN 200004-19-9 CAPLUS
CN Benzene, 4-(3-chloro-1-phenylpropoxy)-1-nitro-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 200004-20-2 CAPLUS
CN Benzonitrile, 4-(3-chloro-1-phenylpropoxy)- (9CI) (CA INDEX NAME)




RN 200004-22-4 CAPLUS
CN Benzene, 1-(3-chloro-1-phenylpropoxy)-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-28-0 CAPLUS
CN Benzonitrile, 4-[3-chloro-1-(4-chlorophenyl)propoxy]- (9CI) (CA INDEX NAME)




RN 200004-29-1 CAPLUS
CN Benzene, 1-bromo-4-[3-chloro-1-(4-chlorophenoxy)propyl]- (9CI) (CA INDEX NAME)



RN 200004-30-4 CAPLUS
CN Benzene, 1-chloro-4-(3-chloro-1-phenoxypropyl)- (9CI) (CA INDEX NAME)




RN 200004-31-5 CAPLUS
CN Benzene, 1-(3-chloro-1-(4-fluorophenyl)propoxy)-4-methoxy- (9CI) (CA INDEX NAME)




RN 200004-32-6 CAPLUS
CN Benzene, 1-(3-chloro-1-phenylpropoxy)-4-fluoro- (9CI) (CA INDEX NAME)

09/757,011

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-33-7 CAPLUS
CN Benzene, 1-[3-chloro-1-(4-fluorophenyl)propoxy]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 200004-34-8 CAPLUS
CN Benzene, 1-[(1R)-3-chloro-1-phenylpropoxy]-4-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 200004-35-9 CAPLUS
CN 1,1'-Biphenyl, 4-[(1S)-3-chloro-1-(4-fluorophenyl)propoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).




RN 200004-36-0 CAPLUS
CN 1,1'-Biphenyl, 4-[(1R)-3-chloro-1-(4-fluorophenyl)propoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200006-72-0 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-(3-oxo-3-phenylpropyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 200006-74-2 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-[3-(4-fluorophenyl)-3-oxopropyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 200006-76-4 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-(3-oxo-3-phenylpropyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 200006-78-6 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-(3-hydroxy-3-phenylpropyl)-, methyl ester (9CI) (CA INDEX NAME)

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-37-1 CAPLUS
CN Tricyclo[3.3.1.1.3,7]decane, 1-[4-[(1R)-3-chloro-1-(4-fluorophenyl)propoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 200006-17-3 CAPLUS
CN Glycine, N-methyl-N-[3-[[4-(4-methylphenyl)sulfonyl]phenylamino]-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200006-20-8 CAPLUS
CN Acetonitrile, [(3,3-diphenylpropyl)amino]- (9CI) (CA INDEX NAME)


Ph2CH-CH2-CH2-NH-CH2-CN

RN 200006-21-9 CAPLUS
CN Acetonitrile, [(3,3-diphenylpropyl)methylamino]- (9CI) (CA INDEX NAME)


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



RN 200006-80-0 CAPLUS
CN 2-Piperidinecarboxylic acid, 1-(3-chloro-3-phenylpropyl)-, methyl ester (9CI) (CA INDEX NAME)




IT 200006-19-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of amino acid derivs. as pharmaceuticals for treatment of
neurol. and neuropsychiatric disorders)
RN 200006-19-5 CAPLUS
CN Benzeneprapanaminium, N-(2-ethoxy-2-oxoethyl)-N,N-dimethyl-.gamma.-[4-(trifluoromethyl)phenoxy]-, iodide (9CI) (CA INDEX NAME)



• 1 -


09/757,011

ANSWER 8 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1982:598350 CAPLUS
 DOCUMENT NUMBER: 97:198350
 TITLE: Synthetic methods for alkyl(pyridine)cobaloximes: 3,3,3-triphenylpropyl- and 1-methylbut-3-enyl(pyridine)cobaloxime
 ASHCROFT, Martin R.; ATKINS, Martin P.; GOLDING, Bernard T.; JOHNSON, Michael D.; SELLARS, Philip J. Dep. Chem., Univ. Coll., London, WC1H 0AJ, UK
 JOURNAL OF CHEMICAL RESEARCH, SYNOPSIS (1982), (8), 216-17
 CODEN: JRPSDC; ISSN: 0308-2342
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 97:198350
 AB 3,3,3-Triphenylpropyl(pyridine)cobaloxime was prepd. in 60% yield by portionwise alternating addn. of solns. of NaBH₄ in EtOH and Ph₃C(CH₂)₂I in C₆H₆ to a soln. of bromo(pyridine)cobaloxime in EtOH under N.
 1-Methylbut-3-enyl(pyridine)cobaloxime, free of isomeric impurities, was prepd. in 73% yield by stirring CoCl₂·6H₂O and dimethylglyoxime in MeOH under N for 30 min, ice cooling, adding sequentially pyridine, 17.3M aq. NaOH, and 1-bromopentene, and stirring for 18 h.
 IT 83584-90-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and reaction with sodium iodide)
 RN 83584-90-1 CAPLUS
 CN Benzenepropanol, .gamma.,.gamma.-diphenyl-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)



ANSWER 10 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1982:35710 CAPLUS
 DOCUMENT NUMBER: 96:35710
 TITLE: Glycinamides
 INVENTOR(S): Van Dorsser, William; Martens, Mark; Gillet, Claude; Niebes, Paul; Roncucci, Romeo; Roba, Joseph; Cordi, Alexis; Lambelin, Georges
 CONTINENTAL PHARMA, BELG.
 BELG., 57 pp.
 CODEN: BEXXAL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 885303	A1	19810319	BE 1980-202158	19800919
PRIORITY APPLN. INFO.: BE 1980-202158 19800919				
AB RRINCH2CONR3R4 (R = optionally alkyl, alkenyl, alkynyl, acyl; R1 = H, alkyl, acyl, alkoxy, carbonyl, H2NCOCH2; R2 = H, alkyl, Ph; R3 = H, alkyl, Ph, halophenyl; R4 = H, alkyl) were prepd. Thus, Me(CH ₂) ₁₇ NH ₂ was treated with ClCH ₂ CONH ₂ to give Me(CH ₂) ₁₇ NHCH ₂ CONH ₂ which was anticonvulsant against bicucullin-induced convulsion in mice at 10-100 mg/kg orally.				
IT 76991-05-4P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. and anticonvulsant activity of) RN 76991-05-4 CAPLUS CN Acetamide, 2-[(3,3-diphenylpropyl)amino]- (9CI) (CA INDEX NAME)				



ANSWER 9 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1982:142447 CAPLUS
 DOCUMENT NUMBER: 96:142447
 TITLE: Aryloxyphenylpropylamines
 INVENTOR(S): Molloy, Bryan B.; Schmeigel, Klaus K.
 PATENT ASSIGNEE(S): Lilly, Eli, and Co., USA
 U.S., 6 pp. Cont.-in-part of U.S. Ser. No. 872,148.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4313896	A	19820202	US 1981-241913	19810309
US 4314081	A	19820202	US 1974-432379	19740110
AT 7602370	A	19761015	AT 1976-2370	19760401
AT 337161	B	19770610		
AT 7602371	A	19761015	AT 1976-2371	19760401
AT 337162	B	19770610		
CS 185698	P	19790430	CS 1977-248	19770114
CS 196397	P	19800331	CS 1977-7781	19771124
PRIORITY APPLN. INFO.: US 1974-432379 19740110				
US 1978-872148 19780125				
AT 1975-102 19750108				
CS 1975-150 19750108				

AB p-F3CC6H4OCHPhCH2CH2NH2 (I) was prepd. from PhCH2CH2CH2Cl by bromination with NBS, substitution reaction of PhCH2CH2CH2Cl with p-F3CC6H4ONa and NaH, and reduct. of the azide function with NaBH₄. The oxalic acid and HCl salts of I are also claimed. I is an antidepressant; data for the blockade of norepinephrine and serotonin uptake are given.
 IT 21763-01-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and ammonolysis of)
 RN 21763-01-9 CAPLUS
 CN Benzene, (3-chloro-1-phenoxypropyl)- (9CI) (CA INDEX NAME)



ANSWER 11 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1981:139256 CAPLUS
 DOCUMENT NUMBER: 94:139256
 TITLE: Glycinamide derivatives and their use
 INVENTOR(S): Roncucci, Romeo; Gillet, Claude; Cordi, Alexis; Martens, Mark; Roba, Joseph; Niebes, Paul; Lambelin, Georges; Van Dorsser, William
 CONTINENTAL PHARMA, BELG.
 GER. OFFEN., 89 pp.
 CODEN: GWXXEX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3010599	A1	19801009	DE 1980-3010599	19800320
DE 3010599	C2	19800302		
DE 3050800	C2	19800622	DE 1980-3050800	19800320
DK 8001235	A	19800923	DK 1980-1235	19800321
DK 162714	B	19911202		
DK 162714	C	19920421		
SE 8002204	A	19800923	SE 1980-2204	19800321
SE 453917	B	19880314		
SE 453917	C	19880623		
FI 8000900	A	19800923	FI 1980-900	19800321
FI 82033	B	19900928		
FI 82033	C	19910110		
NO 8000830	A	19800923	NO 1980-830	19800321
NO 157817	B	19880215		
NO 157817	C	19880525		
FR 2451913	A1	19801017	FR 1980-6390	19800321
FR 2451913	B1	19840713		
ES 490536	A1	19810416	ES 1980-490536	19800321
ZA 8001682	A	19810826	ZA 1980-1682	19800321
CH 645091	A	19840914	CH 1980-2253	19800321
IL 59679	A1	19841130	IL 1980-59679	19800321
AT 8001546	A	19860215	AT 1980-1546	19800321
AT 381302	B	19860925		
JP 55143944	A2	19801110	JP 1980-36806	19800322
JP 63009491	B4	19880229		
NL 8001721	A	19800924	NL 1980-1721	19800324
NL 191508	B	19950418		
NL 191508	C	19950821		
AU 8056784	A1	19800925	AU 1980-56784	19800324
AU 536499	B2	19840510		
GB 2048852	A	19801217	GB 1980-9801	19800324
GB 2048852	B2	19830330		
CA 1184567	A1	19850326	CA 1980-348319	19800324
AT 8402750	A	19900215	AT 1984-2750	19840828
AT 391134	B	19900827		
AT 8402751	A	19900815	AT 1984-2751	19840828
AT 392271	B	19910225		
US 4639468	A	19870127	US 1985-768185	19850823
PRIORITY APPLN. INFO.: LU 1979-81068 19790322				
LU 1979-81069 19790322				
AT 1980-1546 19800321				
US 1980-133102 19800324				
US 1983-465756 19830421				

L44 ANSWER 11 of 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)


AB The amides RN1RCH2CH2CH2NR3R4, R1 = R = C9-18 alkyl, C5-18 alkanyl, C4-10 alkynyl, C4-10 alkoxy, C1-10 hydroxyalkyl, alkoxycarbonylalkyl, acetoxyalkyl, carbonylalkyl, phenoxalkyl, (un)substituted phenylalkyl; R1 = H, C1-10 alkyl, C1-6 acyl, Bz, C1-4 alkoxy, carbonyl, carboxamido, dimethyl; R2 = H, C1-3 alkyl, Ph, R3 = H, C1-8 alkyl, alkenyl, alkenyl; R4 = H, C1-8 alkyl were prep'd. Thus, Me(CH2)17NH2 was treated with ClCH2CONH2 to give Me(CH2)17NHCH2CONH2. I was tested for anticonvulsant activity in mice with bicuculline induced convulsions. The anticonvulsant ED50 of Me(CH2)4NHCH2CONH2 in mice was 11.2 mg/kg.

IT 76991-05-49

RAC Biologic (biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. and anticonvulsant activity of)

RN 76991-05-4 CAPLUS

CN Acetamide, 2-[(3,3-diphenylpropyl)amino]- (9CI) (CA INDEX NAME)




(d)

14 ANSWER 12 OF 15 CAPIUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1977:534520 CAPIUS
DOCUMENT NUMBER: 87:134520
TITLE: Aryloxyphenylpropylamines in treating depression
INVENTOR(S): Mollay, Bryan B.; Schmeigel, Klaus K.
PATENT ASSIGNEE(S): Lilly, Eli. and Co., USA
SOURCE: U.S., 10 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4018895	A	19770419	US 1975-614094	19750917
US 4314081	A	19820202	US 1974-432379	19740110
AU 7476836	P	19760624	AU 1974-76836	19741224
DK 7406889	A	19750901	DK 1974-6889	19741230
DK 140430	B	19790827		
DK 140430	C	19800121		
RO 1463	P	19820225	RO 1974-80996	19741230
RO 70660	P	19830926	RO 1974-90077	19741230
ZA 7500032	A	19760825	ZA 1975-32	19750102
CA 1051034	A1	19790320	CA 1975-217287	19750102
NL 7500186	A	19750714	NL 1975-186	19750107
NL 181654	C	19870504		
NL 181654	C	19871001		
CH 609331	A	19790228	CH 1978-2228	19750107
CH 609332	A	19790228	CH 1978-2229	19750107
CH 609576	A	19790315	CH 1975-102	19750107
AT 17500102	A	19760815	AT 1975-102	19750108
AT 336000	B	19770412		
CS 189680	P	19790430	CS 1975-150	19750108
BE 824255	A1	19750709	BE 1975-1006387	19750109
SE 7500215	A	19750711	SE 1975-215	19750109
SE 412906	B	19800324		
SE 412906	B	19800710		
FR 2257288	A1	19750808	FR 1975-543	19750109
GB 1493961	A	19771207	GB 1975-898	19750109
HU 173723	P	19790728	HU 1975-B1588	19750109
SU 1005655	A3	19830315	SU 1975-2101119	19750109
JP 50101333	A2	19750811	JP 1975-5888	19750110
JP 59039418	B4	19840922		
DD 14613	C	19760122	DD 1975-183594	19750110
ES 433720	A1	19761201	ES 1975-433720	19750110
PL 100330	P	19780930	PL 1975-177267	19750110
PL 101249	P	19781230	PL 1975-196995	19750110
PL 101229	P	19781230	PL 1975-196996	19750110
SU 583743	SU	19771205	SU 1975-2302055	19751226
AT 7602370	A	19761015	AT 1976-2370	19760401
AT 337161	B	19770610		
AT 337161	B	19761015	AT 1976-2371	19760401
AT 337162	B	19770610		
US 1194009	A	19800318	US 1976-723349	19760915
CS 189698	P	19790430	CS 1977-248	19770114

L44	ANSWER 12 OF 15	CAPLUS	COPYRIGHT 2003	CAS ON STN	(Continued)
	CS 196397	P	19800331	CS 1977-77	19771124
PRIORITY APPLN. INFO.:			US 1974-432379		19740119
			AT 1975-102		19750108
			CS 1975-150		19750108
AB	<p>About 50 title amines, most of them of structure <chem>ROCHPhCH2CH2NR1Me</chem> (I: R = Ph, substituted phenyl, naphthyl; R1 = H, Me), or their salts, e.g., hydrochlorides, oxalates, and maleates, useful as psychotropics, particularly as antidepressants, were prepd. Thus, beta-(dimethylamino)propionophenone was reduced with diborane, the resultant alc. was chlorinated with <chem>SOCl2-HCl</chem> in <chem>CHCl3</chem>, and the product was treated with p-<chem>FC6H4ONa</chem> to give I (R = p-<chem>FC6H4</chem>, R1 = Me). I blocked the uptake of physiol. active monoamines, such as serotonin and dopamine. Addnl. I showed activity in antagonizing hypothermia induced by apomorphine and activity in reversing reserpine hypothermia.</p>				
IT	21763-01-9				
	<p>RL: RCT (Reactant); RACT (Reactant or reagent) (reaction of, with ammonia)</p>				
RN	21763-01-9 CAPLUS				
CR	Benzene, (3-chloro-1-phenoxypropyl)- (9CI) (CA INDEX NAME)				




ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN
 REGISTRATION NUMBER: 1975:592800 CAPLUS
 DOCUMENT NUMBER: 83:192809
 TITLE: 3-Aryloxy-3-phenylpropylamines
 INVENTOR(S): Mollay, Bryan B.; Schlegel, Klaus K.
 PATENT ASSIGNEE(S): Lilly, Eli. and Co., USA
 SOURCE: Ger. Offen., 39 pp.
 CODEN: GWXKX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2500110	A1	19750717	DE 1975-2500110	19750103
DE 2500110	C2	19870611		
US 4314081	A	19820200	US 1974-432379	19740110
AU 7476836	A1	19760624	AU 1974-76836	19741224
DK 7468889	A	19750901	DK 1974-6889	19741230
DK 140430	B	19790827		
DK 140430	A	19800117		
RO 69763	F	19820226	RO 1974-80996	19741230
RO 70660	P	19830926	RO 1974-90077	19741230
ZA 7500032	A	19760825	ZA 1975-32	19750102
CA 1051034	A1	19790320	CA 1975-217287	19750102
NL 7500186	A	19750714	NL 1975-186	19750107
NL 181654	B	19870504		
NL 181654	C	19871001		
CH 689331	A	19790228	CH 1978-2228	19750107
CH 609332	A	19790232	CH 1978-2229	19750107
CH 609675	A	19790315	CH 1975-102	19750107
AT 7500102	A	19760815	AT 1975-102	19750108
AT 336000	B	19770412		
CS 189680	P	19790430	CS 1975-150	19750108
BE 824255	A1	19750709	BE 1975-1006387	19750109
SE 7500215	A	19750711	SE 1975-215	19750109
SE 412906	C	19800324		
SE 412906	A	19800710		
FR 7257288	C	19750808	FR 1975-543	19750109
GB 1493968	A	19771207	GB 1975-898	19750109
HU 173723	P	19790728	HU 1975-E1588	19750109
SU 1005655	A3	19830315	SU 1975-2101119	19750109
JP 50101333	A2	19750811	JP 1975-5888	19750110
JP 59039418	B4	19840922		
DD 118613	C	19760312	DD 1975-183594	19750110
ES 433720	A1	19761201	ES 1975-433720	19750110
PL 101230	P	19780909	PL 1975-177267	19750110
PL 101249	P	19781230	PL 1975-196959	19750110
PL 101229	P	19781230	PL 1975-196996	19750110
SU 583744	D	19771205	SU 1975-2302055	19751226
AT 7602370	A	19760105	AT 1976-2370	19760401
AT 337161	B	19770610		
AT 7602371	A	19760105	AT 1976-2371	19760401
AT 337162	B	19770610		
US 4194009	A	19800318	US 1976-723349	19760915
CS 189698	P	19790430	CS 1977-248	19770124
CS 196397	P	19800331	CS 1977-7781	19771124
PRIORITY APPLN. INFO.:			US 1974-432379	19740110
			AT 1975-102	19750108

09/757,011

L44 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 CS 1975-150 19750108
 AB RCGH4OCHPACHRICR2NR3R4 (I) R = H, 3-F, 4-CP3, 3-Me3C, 2-MeO, etc.; R1, R2, R3, R4 = H, Me) were prepd. Thus, PhCO(CH2)2NMe2 was reduced by diborane to PhCH(OH)(CH2)2NMe2, which reacted with HCl in CHCl3 to give PhCHCl(CH2)2NMe2 (II). Reaction of II with 4-F3CC6H4ONa gave I (R = 4-F3C, R1 = R2 = H; R3 = R4 = Me), which reacted with BrCN, then with KOH in HOCH2CH2OH to give I (R = 4-F3C, R1 = R2 = R3 = H, R4 = Me). I was useful as antidepressants; test data were given.
 IT 21763-01-9
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with ammonia)
 RN 21763-01-9 CAPLUS
 CN Benzene, (3-chloro-1-phenoxypropyl)- (9CI) (CA INDEX NAME)



ANSWER 14 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1972:448142 CAPLUS
 DOCUMENT NUMBER: 77:48142
 TITLE: Preparation of flavan by carbocyclization of .omega.-functional 1-phenoxy-1-phenylpropanes. Rearrangement leading to 4-phenylchroman
 AUTHOR(S): Sliwa, Monique; Sliwa, Henri; Maitte, Pierre
 CORPORATE SOURCE: Lab. Chim. XIV, Univ. Paris VI, Paris, Fr.
 SOURCE: Bulletin de la Societe Chimique de France (1972), (4), 1540-4
 CODEN: BSCFAS; ISSN: 0037-8968
 DOCUMENT TYPE: Journal
 LANGUAGE: French
 G1 For diagram(s), see printed CA Issue.
 AB The cyclization of 1-phenoxy-1-phenylpropanes under either Friedel-Crafts or acidic conditions leads to 4-phenylchroman (I) rather than flavan (II) as expected. Thus, heating 3-chloro-1-phenoxy-1-phenylpropane in the presence of SnCl4 gives 25% I with large amts. of tar. The results are interpreted by cleavage of starting materials caused by attack of acid on the ether O to give a benzyl cation which adds electrophilically to the carbon .alpha. to the coupled O, followed by cycloelimination of halogen by the complexed O.
 IT 21763-01-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and cyclization of)
 RN 21763-01-9 CAPLUS
 CN Benzene, (3-chloro-1-phenoxypropyl)- (9CI) (CA INDEX NAME)



ANSWER 15 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1969:77711 CAPLUS
 DOCUMENT NUMBER: 70:77711
 TITLE: Unexpected synthesis of 4-phenylchroman and a new preparation of flavan-3-ylcarbinols
 AUTHOR(S): Sliwa, Monique; Sliwa, Henri; Maitte, Pierre
 CORPORATE SOURCE: Lab. Chim. XIV, Fac. Sci., Paris, Fr.
 SOURCE: Comptes Rendus des Seances de l'Academie des Sciences, Serie C: Sciences Chimiques (1969), 268(3), 263-6
 CODEN: CHDCAQ; ISSN: 0567-6541
 DOCUMENT TYPE: Journal
 LANGUAGE: French
 AB 1-Phenyl-1-phenoxy-3-chloropropane (I) is treated with SnCl4 at 120.degree. and 1-phenyl-1-phenoxy-3-propanol (II) is treated with polyphosphoric acid at 90.degree. to give 4-phenylchroman (III). It is proposed that I and II react with Lewis acids (L) to give PhOL- (IV) and PhO+HCH2CH2X (V) intermediates and V add to IV in an electrophilic substitution to give III. o-Hydroxybenzyl alc. is treated with styrenes to give 3-(carbethoxy)flavan and 3-acetylflavan, which are converted to flavan-3-ylcarbinols.
 IT 21763-01-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 21763-01-9 CAPLUS
 CN Benzene, (3-chloro-1-phenoxypropyl)- (9CI) (CA INDEX NAME)

